Jens J Holst Dmsci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/886838/publications.pdf Version: 2024-02-01

1,104 papers	74,016 citations	466 130 h-index	¹⁵⁹⁹ 216 g-index
1117	1117	1117	39724
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	The Physiology of Glucagon-like Peptide 1. Physiological Reviews, 2007, 87, 1409-1439.	28.8	2,504
2	Type 2 diabetes mellitus. Nature Reviews Disease Primers, 2015, 1, 15019.	30.5	1,308
3	Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet, The, 2002, 359, 824-830.	13.7	1,207
4	Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations. New England Journal of Medicine, 2006, 355, 467-477.	27.0	878
5	Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus. New England Journal of Medicine, 1992, 326, 1316-1322.	27.0	860
6	Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine, 2002, 8, 738-742.	30.7	798
7	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3717-3723.	3.6	767
8	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metabolism, 2017, 26, 611-619.e6.	16.2	689
9	Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences, 1993, 38, 665-673.	2.3	626
10	Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E1209-E1215.	3.5	583
11	Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E199-E206.	3.5	518
12	Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1239-1246.	3.6	515
13	The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on Â-Cell Sensitivity in Type 2 and Nondiabetic Subjects. Diabetes, 2003, 52, 380-386.	0.6	513
14	Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism. Obesity, 2009, 17, 1671-1677.	3.0	501
15	Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine ¹ . Endocrinology, 1999, 140, 5356-5363.	2.8	497
16	Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology, 2001, 120, 806-815.	1.3	490
17	Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4612-4619.	3.6	464
18	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. European Heart Journal, 2012, 33, 1491-1499.	2.2	456

#	Article	IF	CITATIONS
19	Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*. Endocrinology, 1986, 119, 1467-1475.	2.8	455
20	The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology, 2009, 297, 127-136.	3.2	447
21	Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E981-E988.	3.5	423
22	Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. American Journal of Clinical Nutrition, 2004, 80, 1246-1253.	4.7	390
23	Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides, 2003, 114, 115-121.	1.9	360
24	Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients. Diabetes, 2008, 57, 1340-1348.	0.6	353
25	Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3575-3581.	3.6	344
26	Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2719-2725.	3.6	315
27	Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. American Journal of Clinical Nutrition, 2007, 85, 996-1004.	4.7	314
28	Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surgery for Obesity and Related Diseases, 2007, 3, 597-601.	1.2	311
29	Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10293-10298.	7.1	310
30	Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance. Diabetes, 2008, 57, 678-687.	0.6	307
31	Reduced Incretin Effect in Type 2 Diabetes. Diabetes, 2007, 56, 1951-1959.	0.6	297
32	Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans. Diabetes, 2011, 60, 1561-1565.	0.6	291
33	Meals with similar energy densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy expenditure and substrate metabolism but not on appetite and energy intake. American Journal of Clinical Nutrition, 2003, 77, 91-100.	4.7	287
34	GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regulatory Peptides, 2003, 114, 189-196.	1.9	284
35	Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors. Diabetes, 2004, 53, 1326-1335.	0.6	283
36	Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature, 2020, 581, 310-315.	27.8	283

#	Article	IF	CITATIONS
37	Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. American Journal of Clinical Nutrition, 2005, 82, 69-75.	4.7	282
38	Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. Cell Metabolism, 2016, 24, 63-74.	16.2	278
39	Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: a randomised cross-over trial. Gut, 2019, 68, 83-93.	12.1	278
40	Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects. Diabetes, 2004, 53, 654-662.	0.6	277
41	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. Journal of Clinical Investigation, 2003, 112, 1550-1560.	8.2	276
42	Antihyperglycemic effects of stevioside in type 2 diabetic subjects. Metabolism: Clinical and Experimental, 2004, 53, 73-76.	3.4	274
43	Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. American Journal of Clinical Nutrition, 2005, 82, 69-75.	4.7	274
44	Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5991-5997.	3.6	274
45	Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption. Journal of Bone and Mineral Research, 2003, 18, 2180-2189.	2.8	272
46	Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. American Journal of Clinical Nutrition, 1999, 69, 1135-1143.	4.7	270
47	A Major Lineage of Enteroendocrine Cells Coexpress CCK, Secretin, GIP, GLP-1, PYY, and Neurotensin but Not Somatostatin. Endocrinology, 2012, 153, 5782-5795.	2.8	269
48	Glucose-Dependent Insulinotropic Polypeptide. Diabetes, 2011, 60, 3103-3109.	0.6	265
49	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. Diabetes, 2013, 62, 3044-3052.	0.6	262
50	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. Genome Medicine, 2016, 8, 67.	8.2	260
51	Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein–Coupled Bile Acid Receptors. Endocrinology, 2015, 156, 3961-3970.	2.8	253
52	Discovery, characterization, and clinical development of the glucagon-like peptides. Journal of Clinical Investigation, 2017, 127, 4217-4227.	8.2	253
53	Diet- and Colonization-Dependent Intestinal Dysfunction Predisposes to Necrotizing Enterocolitis in Preterm Pigs. Gastroenterology, 2006, 130, 1776-1792.	1.3	249
54	Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes and Endocrinology,the, 2014, 2, 152-164.	11.4	248

#	Article	IF	CITATIONS
55	Postprandial glucose, insulin, and incretin responses to grain products in healthy subjects. American Journal of Clinical Nutrition, 2002, 75, 254-262.	4.7	246
56	Gastric emptying, gastric secretion and enterogastrone response after administration of milk proteins or their peptide hydrolysates in humans. European Journal of Nutrition, 2004, 43, 127-139.	3.9	246
57	Glucagonlike peptide 1: A newly discovered gastrointestinal hormone. Gastroenterology, 1994, 107, 1848-1855.	1.3	245
58	Including Indigestible Carbohydrates in the Evening Meal of Healthy Subjects Improves Glucose Tolerance, Lowers Inflammatory Markers, and Increases Satiety after a Subsequent Standardized Breakfast. Journal of Nutrition, 2008, 138, 732-739.	2.9	243
59	2-Oleoyl Glycerol Is a GPR119 Agonist and Signals GLP-1 Release in Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1409-E1417.	3.6	238
60	GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes, 2015, 64, 2513-2525.	0.6	235
61	The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon. American Journal of Physiology - Renal Physiology, 2018, 315, G53-G65.	3.4	235
62	Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes. Diabetes Care, 2011, 34, S251-S257.	8.6	233
63	Insulin Secretion Depends on Intra-islet Glucagon Signaling. Cell Reports, 2018, 25, 1127-1134.e2.	6.4	233
64	The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action. Diabetes, 2010, 59, 1765-1770.	0.6	230
65	Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Archiv European Journal of Physiology, 1998, 435, 583-594.	2.8	227
66	Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3717-3723.	3.6	224
67	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. Diabetes, 2014, 63, 1725-1737.	0.6	220
68	The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1249-1255.	3.6	219
69	Glucagon-Like Peptide 2 Stimulates Glucagon Secretion, Enhances Lipid Absorption, and Inhibits Gastric Acid Secretion in Humans. Gastroenterology, 2006, 130, 44-54.	1.3	218
70	Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Scientific Reports, 2017, 7, 2360.	3.3	216
71	GLP-2 Receptor Localizes to Enteric Neurons and Endocrine Cells Expressing Vasoactive Peptides and Mediates Increased Blood Flow. Gastroenterology, 2006, 130, 150-164.	1.3	214
72	GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1746-E1755.	3.5	211

#	Article	IF	CITATIONS
73	Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough?. American Journal of Clinical Nutrition, 2000, 71, 1603-1610.	4.7	210
74	Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology, 2003, 124, 894-902.	1.3	205
75	Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 937-942.	7.1	204
76	Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. American Journal of Clinical Nutrition, 2009, 89, 106-113.	4.7	201
77	Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Scientific Reports, 2019, 9, 12515.	3.3	200
78	lleal release of glucagon-like peptide-1 (GLP-1). Digestive Diseases and Sciences, 1995, 40, 1074-1082.	2.3	199
79	Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides, 2000, 21, 73-80.	2.4	196
80	Intake of <i>Lactobacillus reuteri</i> Improves Incretin and Insulin Secretion in Glucose-Tolerant Humans: A Proof of Concept. Diabetes Care, 2015, 38, 1827-1834.	8.6	194
81	Effects of PYY1–36and PYY3–36on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E1062-E1068.	3.5	192
82	Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 737-745.	3.6	190
83	Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Molecular Systems Biology, 2016, 12, 901.	7.2	188
84	Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. European Journal of Pharmacology, 2000, 404, 239-245.	3.5	184
85	Effect of a high-protein breakfast on the postprandial ghrelin response. American Journal of Clinical Nutrition, 2006, 83, 211-220.	4.7	181
86	GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regulatory Peptides, 2005, 124, 105-112.	1.9	179
87	Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes. American Journal of Clinical Nutrition, 2003, 77, 605-611.	4.7	178
88	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020, 5, .	5.0	177
89	Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism: Clinical and Experimental, 1994, 43, 104-108.	3.4	176
90	Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. Expert Opinion on Investigational Drugs, 2004, 13, 1091-1102.	4.1	176

#	Article	IF	CITATIONS
91	Plasma proteome profiling discovers novel proteins associated with nonâ€alcoholic fatty liver disease. Molecular Systems Biology, 2019, 15, e8793.	7.2	176
92	Structural differences between rye and wheat breads but not total fiber content may explain the lower postprandial insulin response to rye bread. American Journal of Clinical Nutrition, 2003, 78, 957-964.	4.7	173
93	Early Differential Defects of Insulin Secretion and Action in 19-Year-Old Caucasian Men Who Had Low Birth Weight. Diabetes, 2002, 51, 1271-1280.	0.6	172
94	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 2021, 384, 1719-1730.	27.0	171
95	Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia, 2016, 59, 2156-2165.	6.3	169
96	Effect of dairy calcium or supplementary calcium intake on postprandial fat metabolism, appetite, and subsequent energy intake. American Journal of Clinical Nutrition, 2007, 85, 678-687.	4.7	168
97	GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1 1This work is a publication of the USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas Gastroenterology, 2003, 125, 136-147.	1.3	165
98	GPR119 as a fat sensor. Trends in Pharmacological Sciences, 2012, 33, 374-381.	8.7	165
99	Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. Clinical Science, 2016, 130, 2073-2082.	4.3	165
100	Incretin Hormone and Insulin Responses to Oral <i>Versus</i> Intravenous Lipid Administration in Humans. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2519-2524.	3.6	161
101	GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 277, R910-R916.	1.8	160
102	Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets. Journal of Parenteral and Enteral Nutrition, 2004, 28, 210-222.	2.6	157
103	Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Digestive Diseases and Sciences, 1991, 36, 1361-1370.	2.3	156
104	The use of glycaemic index tables to predict glycaemic index of composite breakfast meals. British Journal of Nutrition, 2004, 91, 979-989.	2.3	156
105	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. Diabetologia, 2014, 57, 1919-1926.	6.3	156
106	Roles of the Gut in Glucose Homeostasis. Diabetes Care, 2016, 39, 884-892.	8.6	155
107	Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends in Molecular Medicine, 2008, 14, 161-168.	6.7	152
108	Increased Postprandial GIP and Glucagon Responses, But Unaltered GLP-1 Response after Intervention with Steroid Hormone, Relative Physical Inactivity, And High-Calorie Diet in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 447-453.	3.6	152

#	Article	IF	CITATIONS
109	Insulin Resistance Alters Islet Morphology in Nondiabetic Humans. Diabetes, 2014, 63, 994-1007.	0.6	152
110	The prebiotic inulin improves substrate metabolism and promotes short-chain fatty acid production in overweight to obese men. Metabolism: Clinical and Experimental, 2018, 87, 25-35.	3.4	152
111	Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E664-E671.	3.6	151
112	Supplementation of Diet With Galacto-oligosaccharides Increases Bifidobacteria, but Not Insulin Sensitivity, inÂObeseÂPrediabetic Individuals. Gastroenterology, 2017, 153, 87-97.e3.	1.3	150
113	Therapy of type 2 diabetes mellitus based on the actions of glucagonâ€like peptideâ€1. Diabetes/Metabolism Research and Reviews, 2002, 18, 430-441.	4.0	149
114	Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. American Journal of Physiology - Renal Physiology, 2007, 293, G211-G221.	3.4	149
115	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E1038-E1046.	3.5	148
116	Effects of Splanchnic Nerve Stimulation on the Adrenal Cortex May Be Mediated by Chromaffin Cells in a Paracrine Manner. Endocrinology, 1990, 127, 900-906.	2.8	147
117	Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance. Diabetes Care, 2008, 31, 30-35.	8.6	147
118	Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. European Journal of Endocrinology, 1996, 135, 425-432.	3.7	146
119	Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2513-2517.	3.6	146
120	Four-month treatment with GLP-2 significantly increases hip BMD. Bone, 2009, 45, 833-842.	2.9	144
121	Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis. Diabetes, 2017, 66, 235-240.	0.6	144
122	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. Surgery for Obesity and Related Diseases, 2018, 14, 708-714.	1.2	144
123	Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function. Diabetes Care, 2011, 34, 1463-1468.	8.6	143
124	Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1096-H1102.	3.2	141
125	GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes. Diabetes, 2011, 60, 1270-1276.	0.6	141
126	Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. Journal of Clinical Investigation, 2003, 112, 1550-1560.	8.2	140

#	Article	IF	CITATIONS
127	The Melanocortin-4 Receptor Is Expressed in Enteroendocrine L Cells and Regulates the Release of Peptide YY and Glucagon-like Peptide 1 InÂVivo. Cell Metabolism, 2014, 20, 1018-1029.	16.2	139
128	Circulating leptin and thyroid dysfunction. European Journal of Endocrinology, 2003, 149, 257-271.	3.7	138
129	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology - Renal Physiology, 2013, 304, G1117-G1127.	3.4	138
130	Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. Diabetes, 2016, 65, 3473-3481.	0.6	137
131	Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes, 2016, 65, 585-597.	0.6	136
132	Glucagon-Like Peptide 2 Dose-Dependently Activates Intestinal Cell Survival and Proliferation in Neonatal Piglets. Endocrinology, 2005, 146, 22-32.	2.8	135
133	Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety. American Journal of Clinical Nutrition, 2013, 97, 980-989.	4.7	135
134	Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA Psychiatry, 2017, 74, 719.	11.0	135
135	Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Molecular Metabolism, 2018, 11, 84-95.	6.5	135
136	Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice. Endocrinology, 2011, 152, 3018-3029.	2.8	134
137	Molecular Mechanisms of Glucose-Stimulated GLP-1 Secretion From Perfused Rat Small Intestine. Diabetes, 2015, 64, 370-382.	0.6	132
138	Importance of Small Bowel Peptides for the Improved Glucose Metabolism 20 Years after Jejunoileal Bypass for Obesity. Obesity Surgery, 1998, 8, 253-260.	2.1	131
139	Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function. Diabetes, 2011, 60, 1599-1607.	0.6	131
140	The effect of glucagon-like peptide 1 on cardiovascular risk. Nature Reviews Cardiology, 2012, 9, 209-222.	13.7	131
141	Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine. Endocrinology, 1999, 140, 5356-5363.	2.8	129
142	An Analysis of Cosecretion and Coexpression of Gut Hormones From Male Rat Proximal and Distal Small Intestine. Endocrinology, 2015, 156, 847-857.	2.8	128
143	Secretion and Dipeptidyl Peptidase-4-Mediated Metabolism of Incretin Hormones after a Mixed Meal or Glucose Ingestion in Obese Compared to Lean, Nondiabetic Men. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 872-878.	3.6	127
144	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 221-232.	11.4	127

#	Article	IF	CITATIONS
145	The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism: Clinical and Experimental, 2019, 96, 46-55.	3.4	127
146	In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2884-2888.	3.6	126
147	The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose. Diabetes Care, 2008, 31, 108-113.	8.6	126
148	Natural History of Insulin Sensitivity and Insulin Secretion in the Progression From Normal Glucose Tolerance to Impaired Fasting Glycemia and Impaired Glucose Tolerance: The Inter99 Study. Diabetes Care, 2009, 32, 439-444.	8.6	126
149	Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans. Diabetes, 2010, 59, 2160-2163.	0.6	126
150	Neuroprotective properties of GLP-1: theoretical and practical applications. Current Medical Research and Opinion, 2011, 27, 547-558.	1.9	125
151	Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 3346-3352.	8.6	125
152	Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 473-478.	3.6	124
153	Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects. American Journal of Clinical Nutrition, 2009, 89, 815-821.	4.7	123
154	Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. American Journal of Clinical Nutrition, 2009, 90, 41-48.	4.7	122
155	Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. American Journal of Physiology - Endocrinology and Metabolism, 2000, 278, E1010-E1018.	3.5	119
156	Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism. Endocrinology, 2016, 157, 176-194.	2.8	119
157	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes, 2019, 68, 906-917.	0.6	118
158	Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E621-E625.	3.5	117
159	Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential. Trends in Endocrinology and Metabolism, 1999, 10, 229-235.	7.1	116
160	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. European Journal of Endocrinology, 2014, 170, 529-538.	3.7	116
161	GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2909-2917.	3.6	116
162	Effects of PYY _{3–36} and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E1248-E1256.	3.5	114

#	Article	IF	CITATIONS
163	Erythromycin Antagonizes the Deceleration of Gastric Emptying by Glucagon-Like Peptide 1 and Unmasks Its Insulinotropic Effect in Healthy Subjects. Diabetes, 2005, 54, 2212-2218.	0.6	113
164	Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 459-464.	3.6	113
165	Glucagon Receptor Signaling and Glucagon Resistance. International Journal of Molecular Sciences, 2019, 20, 3314.	4.1	113
166	Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs, 2010, 19, 133-140.	4.1	112
167	Glucagon Receptor Signaling and Lipid Metabolism. Frontiers in Physiology, 2019, 10, 413.	2.8	112
168	Oxyntomodulin from distal gut. Digestive Diseases and Sciences, 1989, 34, 1411-1419.	2.3	111
169	Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—Current status. Gastroenterology, 1983, 84, 1602-1613.	1.3	110
170	The Liver–α-Cell Axis and Type 2 Diabetes. Endocrine Reviews, 2019, 40, 1353-1366.	20.1	110
171	Human galanin: Primary structure and indentification of two molecular forms. FEBS Letters, 1991, 283, 189-194.	2.8	109
172	Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacology, 2004, 4, 589-596.	3.5	108
173	Effect of liraglutide on ectopic fat in polycystic ovary syndrome: <scp>A</scp> randomized clinical trial. Diabetes, Obesity and Metabolism, 2018, 20, 215-218.	4.4	108
174	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia, 2018, 61, 284-294.	6.3	107
175	Disassociation of bone resorption and formation by GLP-2. Bone, 2007, 40, 723-729.	2.9	106
176	Onset of Small Intestinal Atrophy Is Associated with Reduced Intestinal Blood Flow in TPN-Fed Neonatal Piglets. Journal of Nutrition, 2004, 134, 1467-1474.	2.9	105
177	Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides, 2004, 122, 209-217.	1.9	105
178	Sulfonylurea Compounds Uncouple the Glucose Dependence of the Insulinotropic Effect of Glucagon-Like Peptide 1. Diabetes, 2007, 56, 438-443.	0.6	105
179	The Dipeptidyl Peptidase 4 Inhibitor Vildagliptin Does Not Accentuate Glibenclamide-Induced Hypoglycemia but Reduces Glucose-Induced Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide Secretion. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4165-4171.	3.6	105
180	Association of Type 2 Diabetes Candidate Polymorphisms in <i>KCNQ1</i> With Incretin and Insulin Secretion. Diabetes, 2009, 58, 1715-1720.	0.6	105

#	Article	IF	CITATIONS
181	Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion. Diabetes Care, 2010, 33, 375-377.	8.6	105
182	Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scandinavian Journal of Gastroenterology, 2009, 44, 314-319.	1.5	104
183	Loss of Inverse Relationship Between Pulsatile Insulin and Glucagon Secretion in Patients With Type 2 Diabetes. Diabetes, 2011, 60, 2160-2168.	0.6	104
184	Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2325-E2329.	3.6	104
185	The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides, 1984, 9, 35-46.	1.9	103
186	Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone, 2004, 34, 140-147.	2.9	103
187	Distinct Effects of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 on Insulin Secretion and Gut Motility. Diabetes, 2005, 54, 1056-1063.	0.6	103
188	Enteral bile acid treatment improves parenteral nutrition-related liver disease and intestinal mucosal atrophy in neonatal pigs. American Journal of Physiology - Renal Physiology, 2012, 302, G218-G224.	3.4	103
189	Wheat-fibre-induced changes of postprandial peptide YY and ghrelin responses are not associated with acute alterations of satiety. British Journal of Nutrition, 2006, 96, 795-798.	2.3	102
190	Comparison of the effects on insulin resistance and glucose tolerance of 6-mo high-monounsaturated-fat, low-fat, and control diets. American Journal of Clinical Nutrition, 2008, 87, 855-862.	4.7	102
191	Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy, 2013, 14, 2047-2058.	1.8	102
192	Consumption of a Diet Low in Advanced Glycation End Products for 4 Weeks Improves Insulin Sensitivity in Overweight Women. Diabetes Care, 2014, 37, 88-95.	8.6	102
193	The biology of glucagon and the consequences of hyperglucagonemia. Biomarkers in Medicine, 2016, 10, 1141-1151.	1.4	102
194	Combinatorial, additive and dose-dependent drug–microbiome associations. Nature, 2021, 600, 500-505.	27.8	102
195	A Cereal-Based Evening Meal Rich in Indigestible Carbohydrates Increases Plasma Butyrate the Next Morning ,. Journal of Nutrition, 2010, 140, 1932-1936.	2.9	101
196	Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Digestive Diseases and Sciences, 1998, 43, 2284-2290.	2.3	100
197	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. Diabetologia, 2013, 56, 2250-2254.	6.3	100
198	Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. International Journal of Biochemistry and Cell Biology, 2006, 38, 831-844.	2.8	99

#	Article	IF	CITATIONS
199	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. Gastroenterology, 2019, 156, 1627-1641.e1.	1.3	99
200	Oxyntomodulin (glicentin-(33–69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regulatory Peptides, 1988, 21, 151-166.	1.9	98
201	Long-Term Effects of Bariatric Surgery on Meal Disposal and β-Cell Function in Diabetic and Nondiabetic Patients. Diabetes, 2013, 62, 3709-3717.	0.6	98
202	A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial. Diabetologia, 2019, 62, 2066-2078.	6.3	98
203	Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. European Journal of Endocrinology, 1993, 128, 207-214.	3.7	97
204	Effects of Free Fatty Acids Per Se on Glucose Production, Gluconeogenesis, and Glycogenolysis. Diabetes, 2003, 52, 260-267.	0.6	97
205	Cecal Infusion of Butyrate Increases Intestinal Cell Proliferation in Piglets. Journal of Nutrition, 2007, 137, 916-922.	2.9	97
206	GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2710-e2716.	3.6	97
207	Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1. Endocrinology, 2004, 145, 1349-1355.	2.8	96
208	Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. American Journal of Physiology - Renal Physiology, 2010, 298, G419-G424.	3.4	96
209	Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Current Opinion in Pharmacology, 2013, 13, 983-988.	3.5	96
210	The <i>CTRB1/2</i> Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway. Diabetes, 2013, 62, 3275-3281.	0.6	96
211	Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. American Journal of Physiology - Renal Physiology, 1998, 275, G984-G992.	3.4	94
212	Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. American Journal of Physiology - Renal Physiology, 2014, 306, G622-G630.	3.4	94
213	Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial. Diabetes Care, 2014, 37, 1797-1805.	8.6	94
214	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia, 2015, 58, 2254-2258.	6.3	94
215	Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia, 2017, 60, 531-540.	6.3	94
216	Effects of insulin on glucose turnover rates in vivo: Isotope dilution versus constant specific activity technique. Metabolism: Clinical and Experimental, 1996, 45, 82-91.	3.4	92

#	Article	IF	CITATIONS
217	Increased circulating leptin in alcoholic cirrhosis: Relation to release and disposal. Hepatology, 1999, 29, 1818-1824.	7.3	92
218	Prohormone Convertase 1/3 Is Essential for Processing of the Glucose-dependent Insulinotropic Polypeptide Precursor. Journal of Biological Chemistry, 2006, 281, 11050-11057.	3.4	92
219	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E324-E330.	3.5	92
220	The Rate of Intestinal Glucose Absorption Is Correlated with Plasma Glucose-Dependent Insulinotropic Polypeptide Concentrations in Healthy Men. Journal of Nutrition, 2006, 136, 1511-1516.	2.9	91
221	Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care, 2015, 38, 2250-2257.	8.6	91
222	The hypothalamic satiety peptide CART is expressed in anorectic and nonâ€anorectic pancreatic islet tumors and in the normal islet of Langerhans. FEBS Letters, 1999, 447, 139-143.	2.8	90
223	Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regulatory Peptides, 2005, 128, 97-107.	1.9	90
224	The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E1118-E1123.	3.5	90
225	Preserved Inhibitory Potency of GLP-1 on Clucagon Secretion in Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4679-4687.	3.6	89
226	Comparative effect of orally administered sodium butyrate before or after weaning on growth and several indices of gastrointestinal biology of piglets. British Journal of Nutrition, 2009, 102, 1285-1296.	2.3	89
227	Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. American Journal of Physiology - Renal Physiology, 2015, 308, F867-F877.	2.7	89
228	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E396-E406.	3.6	89
229	Do we know the true mechanism of action of the <scp>DPP</scp> â€4 inhibitors?. Diabetes, Obesity and Metabolism, 2018, 20, 34-41.	4.4	89
230	Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. American Journal of Physiology - Renal Physiology, 2001, 281, G752-G763.	3.4	88
231	The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on β-cells. Nutrition and Metabolism, 2012, 9, 48.	3.0	88
232	The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor. Diabetes, 2017, 66, 2363-2371.	0.6	88
233	Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes. Trends in Endocrinology and Metabolism, 2017, 28, 88-103.	7.1	88
234	Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metabolism, 2018, 28, 23-32.e3.	16.2	88

#	Article	IF	CITATIONS
235	Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Critical Care Medicine, 2004, 32, 848-851.	0.9	87
236	Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E604-E609.	3.5	87
237	Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT. Journal of Clinical Pharmacology, 2007, 47, 633-641.	2.0	87
238	Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in control of fluid and bicarbonate secretion. Regulatory Peptides, 1984, 8, 245-259.	1.9	86
239	The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism. Diabetes, 2004, 53, S197-S204.	0.6	86
240	GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Molecular and Cellular Endocrinology, 2007, 276, 18-23.	3.2	86
241	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight, 2018, 3, .	5.0	86
242	Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scandinavian Journal of Clinical and Laboratory Investigation, 1987, 47, 165-174.	1.2	86
243	Atlas of exercise metabolism reveals time-dependent signatures of metabolic homeostasis. Cell Metabolism, 2022, 34, 329-345.e8.	16.2	86
244	GLP-1-(9–36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E873-E879.	3.5	85
245	Neural regulation of glucagon-like peptide-1 secretion in pigs. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E939-E947.	3.5	85
246	Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus. Clinical Pharmacokinetics, 2007, 46, 577-588.	3.5	85
247	Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 491-499.	2.5	85
248	Glutamine Reduces Postprandial Glycemia and Augments the Glucagon-Like Peptide-1 Response in Type 2 Diabetes Patients. Journal of Nutrition, 2011, 141, 1233-1238.	2.9	85
249	Specificity and sensitivity of commercially available assays for glucagonâ€like peptideâ€1 (<scp>GLP</scp> â€1): implications for <scp>GLP</scp> â€1 measurements in clinical studies. Diabetes, Obesity and Metabolism, 2014, 16, 1155-1164.	4.4	85
250	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. PLoS ONE, 2015, 10, e0142352.	2.5	85
251	Defining the Role of CLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade. Diabetes, 2014, 63, 1079-1092.	0.6	84
252	Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E93-E103.	3.5	84

#	Article	IF	CITATIONS
253	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. Diabetes Care, 2019, 42, 1446-1453.	8.6	84
254	Nervous control of pancreatic exocrine secretion in pigs. Acta Physiologica Scandinavica, 1979, 105, 33-51.	2.2	83
255	Enteral Feeding Without Pancreatic Stimulation. Pancreas, 2005, 31, 353-359.	1.1	83
256	G Protein-Coupled Receptor 39 Deficiency Is Associated with Pancreatic Islet Dysfunction. Endocrinology, 2009, 150, 2577-2585.	2.8	82
257	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. Diabetologia, 2013, 56, 2679-2687.	6.3	82
258	Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regulatory Peptides, 2012, 179, 91-100.	1.9	81
259	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia, 2019, 62, 665-675.	6.3	81
260	Little enhancement of mealâ€induced glucagonâ€like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. Journal of Diabetes Investigation, 2010, 1, 56-59.	² 2.4	80
261	Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and "lsoglycemic―Intravenous Glucose. Diabetes, 2014, 63, 663-674.	0.6	80
262	Early gradual feeding with bovine colostrum improves gut function and NEC resistance relative to infant formula in preterm pigs. American Journal of Physiology - Renal Physiology, 2015, 309, G310-G323.	3.4	80
263	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. Cell Systems, 2018, 7, 601-612.e3.	6.2	80
264	Acute Effects of Ghrelin Administration on Glucose and Lipid Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 438-444.	3.6	79
265	Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E418-E426.	3.6	79
266	Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opinion on Emerging Drugs, 2004, 9, 155-166.	2.4	78
267	The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. Journal of Pediatric Surgery, 2010, 45, 987-995.	1.6	78
268	Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiological Reports, 2015, 3, e12551.	1.7	78
269	Orlistat Inhibition of Intestinal Lipase Acutely Increases Appetite and Attenuates Postprandial Glucagon-Like Peptide-1-(7–36)-Amide-1, Cholecystokinin, and Peptide YY Concentrations. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3995-3998.	3.6	77
270	The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regulatory Peptides, 2011, 168, 32-38.	1.9	77

#	Article	IF	CITATIONS
271	The effects of l-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans. American Journal of Clinical Nutrition, 2011, 94, 472-478.	4.7	77
272	Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose tolerance. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E1144-E1150.	3.5	76
273	Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice. Diabetes, 2006, 55, 2843-2848.	0.6	76
274	Peptide production and secretion in GLUTag, NCI-H716, and STC-1 cells: a comparison to native L-cells. Journal of Molecular Endocrinology, 2016, 56, 201-211.	2.5	76
275	Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. Diabetologia, 2018, 61, 671-680.	6.3	76
276	Improved tolerance to sequential glucose loading (Staub-Traugott effect): size and mechanisms. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E532-E537.	3.5	74
277	Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations—Role of Carbohydrate and Energy Availability. Diabetes, 2018, 67, 2129-2136.	0.6	74
278	Neuropeptides and Morphological Changes in Cisplatin-Induced Dorsal Root Ganglion Neuronopathy. Experimental Neurology, 1996, 138, 93-104.	4.1	73
279	The truncated metabolite GLP-2 (3–33) interacts with the GLP-2 receptor as a partial agonist. Regulatory Peptides, 2002, 103, 9-15.	1.9	73
280	Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. American Journal of Physiology - Renal Physiology, 2003, 284, G670-G682.	3.4	73
281	Stimulation of Insulin Secretion by Intravenous Bolus Injection and Continuous Infusion of Gastric Inhibitory Polypeptide in Patients With Type 2 Diabetes and Healthy Control Subjects. Diabetes, 2004, 53, S220-S224.	0.6	73
282	Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regulatory Peptides, 2004, 118, 11-18.	1.9	73
283	GLPâ€1: physiological effects and potential therapeutic applications. Diabetes, Obesity and Metabolism, 2008, 10, 994-1003.	4.4	73
284	Effect of viscosity on appetite and gastro-intestinal hormones. Physiology and Behavior, 2009, 97, 68-75.	2.1	73
285	Interleukin-6 Delays Gastric Emptying in Humans with Direct Effects on Glycemic Control. Cell Metabolism, 2018, 27, 1201-1211.e3.	16.2	73
286	Reference intervals for glucose, β-cell polypeptides, and counterregulatory factors during prolonged fasting. American Journal of Physiology - Endocrinology and Metabolism, 2001, 280, E50-E58.	3.5	72
287	The effects of dietary fibre type on satiety-related hormones and voluntary food intake in dogs. British Journal of Nutrition, 2009, 102, 318-325.	2.3	72
288	Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia, 2015, 58, 2688-2698.	6.3	72

#	Article	IF	CITATIONS
289	Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3–36. European Journal of Endocrinology, 2016, 174, 775-784.	3.7	72
290	The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2364-2372.	3.6	72
291	Radioimmunoassay, pharmacokinetics, and neuronal release of gastrin-releasing peptide in anesthetized pigs. Gastroenterology, 1984, 87, 372-378.	1.3	71
292	Gastrin-Releasing Peptide: Pharmacokinetics and Effects on Gastro-Entero-Pancreatic Hormones and Gastric Secretion In Normal Men*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 310-315.	3.6	71
293	Characterization of GLP-1 Effects on Â-Cell Function After Meal Ingestion in Humans. Diabetes Care, 2003, 26, 2860-2864.	8.6	71
294	Increased postprandial glycaemia, insulinemia, and lipidemia after 10 weeks' sucrose-rich diet compared to an artificially sweetened diet: a randomised controlled trial. Food and Nutrition Research, 2011, 55, 5961.	2.6	71
295	Insulin and Clucagon: Partners for Life. Endocrinology, 2017, 158, 696-701.	2.8	71
296	From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy. Frontiers in Endocrinology, 2019, 10, 260.	3.5	71
297	Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regulatory Peptides, 2007, 143, 64-68.	1.9	70
298	Lixisenatide for type 2 diabetes mellitus. Expert Opinion on Investigational Drugs, 2011, 20, 549-557.	4.1	70
299	Mechanisms behind the superior effects of interval vs continuous training on glycaemic control in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia, 2014, 57, 2081-2093.	6.3	70
300	Gut Hormones and Their Effect on Bone Metabolism. Potential Drug Therapies in Future Osteoporosis Treatment. Frontiers in Endocrinology, 2019, 10, 75.	3.5	70
301	Substance P and neurokinin A are codistributed and colocalized in the porcine gastrointestinal tract. Peptides, 1991, 12, 963-973.	2.4	68
302	Assessment of Hepatic Insulin Action in Obese Type 2 Diabetic Patients. Diabetes, 2001, 50, 1363-1370.	0.6	68
303	Histochemical, pharmacological, biochemical and chromatographic evidence that pituitary adenylyl cyclase activating peptide is involved in inhibitory neurotransmission in the taenia of the guinea-pig caecum. Journal of the Autonomic Nervous System, 1995, 50, 311-322.	1.9	67
304	GLP-2 Levels in Infants With Intestinal Dysfunction. Pediatric Research, 2004, 56, 371-376.	2.3	67
305	The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. British Journal of Nutrition, 2009, 101, 1846-1858.	2.3	67
306	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E832-E837.	3.5	67

#	Article	IF	CITATIONS
307	Shortâ€term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: <scp>A</scp> randomized openâ€label crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1479-1484.	4.4	67
308	DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Frontiers in Bioscience - Landmark, 2008, 13, 1780.	3.0	67
309	Inhibition of Gastric Acid Secretion in Man by Exogenous and Endogenous Pancreatic Glucagon. Gastroenterology, 1976, 70, 688-692.	1.3	66
310	Short Term Insulin Treatment Prevents the Diabetogenic Action of Streptozotocin in Rats ¹ . Endocrinology, 1997, 138, 62-68.	2.8	66
311	Diurnal metabolic profiles after 14 d of an ad libitum high-starch, high-sucrose, or high-fat diet in normal-weight never-obese and postobese women. American Journal of Clinical Nutrition, 2001, 73, 177-189.	4.7	66
312	Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Advances in Therapy, 2009, 26, 488-499.	2.9	66
313	Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia, 2011, 54, 2206-2208.	6.3	66
314	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1066-E1071.	3.6	66
315	The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia, 2017, 60, 1731-1739.	6.3	66
316	CIP(3-30)NH2 is an efficacious CIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia, 2018, 61, 413-423.	6.3	66
317	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. Molecular Metabolism, 2020, 42, 101080.	6.5	66
318	Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E849-E856.	3.5	65
319	Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocrine Connections, 2015, 4, 50-57.	1.9	65
320	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4541-4552.	3.6	65
321	Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1043-1048.	3.6	64
322	On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. American Journal of Physiology - Endocrinology and Metabolism, 2010, 298, E614-E621.	3.5	64
323	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 288-294.	3.6	64
324	Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E641-E649.	3.5	63

#	Article	IF	CITATIONS
325	Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 714-722.	3.6	63
326	Glycemic and insulinemic responses as determinants of appetite in humans. American Journal of Clinical Nutrition, 2006, 84, 1365-1373.	4.7	62
327	Patients with psoriasis are insulin resistant. Journal of the American Academy of Dermatology, 2015, 72, 599-605.	1.2	62
328	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E535-E544.	3.5	62
329	Liraglutide for Type 2 diabetes and obesity: a 2015 update. Expert Review of Cardiovascular Therapy, 2015, 13, 753-767.	1.5	62
330	Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care, 2016, 39, 206-213.	8.6	62
331	Introduction of Enteral Food Increases Plasma GLP-2 and Decreases GLP-2 Receptor mRNA Abundance during Pig Development. Journal of Nutrition, 2003, 133, 1781-1786.	2.9	61
332	Impaired Incretin-Induced Amplification of Insulin Secretion after Glucose Homeostatic Dysregulation in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1363-1370.	3.6	61
333	KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia. Diabetes, 2014, 63, 1315-1325.	0.6	61
334	Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Journal of Diabetes and Its Complications, 2015, 29, 445-450.	2.3	61
335	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. American Journal of Physiology - Renal Physiology, 2018, 314, G91-G96.	3.4	61
336	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides, 2020, 125, 170183.	2.4	61
337	Effects of Pre-Meal Drinks with Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal. PLoS ONE, 2012, 7, e44731.	2.5	61
338	The arcuate nucleus is pivotal in mediating the anorectic effects of centrally administered leptin. NeuroReport, 1999, 10, 1183-1187.	1.2	60
339	Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as "lsoglycemic―Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 945-954.	3.6	60
340	Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes. Diabetes, 2015, 64, 72-78.	0.6	60
341	Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care, 2017, 40, 132-135.	8.6	60
342	Leptin Levels Are Associated with Fat Oxidation and Dietaryâ€Induced Weight Loss in Obesity. Obesity, 2001, 9, 452-461.	4.0	59

#	Article	IF	CITATIONS
343	Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regulatory Peptides, 2002, 105, 173-179.	1.9	59
344	The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. Regulatory Peptides, 2002, 110, 39-45.	1.9	59
345	The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans. American Journal of Clinical Nutrition, 2015, 102, 548-555.	4.7	59
346	Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surgery for Obesity and Related Diseases, 2016, 12, 1236-1242.	1.2	59
347	The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs. BMC Research Notes, 2016, 9, 60.	1.4	59
348	Oxyntomodulin: Actions and role in diabetes. Peptides, 2018, 100, 48-53.	2.4	59
349	Incretin Effect After Oral Amino Acid Ingestion in Humans. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1172-1176.	3.6	58
350	Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery. Endocrinology, 2016, 157, 3482-3492.	2.8	58
351	No direct effect of SGLT2 activity on glucagon secretion. Diabetologia, 2019, 62, 1011-1023.	6.3	58
352	Heterogeneity of somatostatin like immunoreactivity (SLI) in extracts of porcine, canine and human pancreas. European Journal of Endocrinology, 1981, 98, 564-572.	3.7	57
353	Intestinal growth adaptation and glucagon-like peptide 2 in rats with ilealjejunal transposition or small bowel resection. Digestive Diseases and Sciences, 2001, 46, 379-388.	2.3	57
354	Gut Transit Is Associated With Gastrointestinal Symptoms and Gut Hormone Profile in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2009, 7, 346-352.	4.4	57
355	Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5703-5714.	3.6	57
356	Glucagon-like Peptide-1, AGastrointestinalHormone with a Pharmaceutical Potential. Current Medicinal Chemistry, 1999, 6, 1005-1017.	2.4	57
357	Regulatory peptides in the lower esophageal sphincter of man. Regulatory Peptides, 1985, 10, 167-178.	1.9	56
358	Role of the Vasoactive Intestinal Peptide in a Neuroendocrine Regulation of the Adrenal Cortex. Neuroendocrinology, 1991, 54, 623-628.	2.5	56
359	Secretion of Glucagon-Like Peptide-1 and Reactive Hypoglycemia after Partial Gastrectomy. Digestion, 1994, 55, 221-228.	2.3	56
360	Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5472-5478.	2.2	56

#	Article	IF	CITATIONS
361	Combining <scp>GLP</scp> â€1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes, Obesity and Metabolism, 2013, 15, 3-14.	4.4	56
362	Acute differential effects of dietary protein quality on postprandial lipemia in obese non-diabetic subjects. Nutrition Research, 2013, 33, 34-40.	2.9	56
363	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. European Journal of Endocrinology, 2014, 171, 407-419.	3.7	56
364	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. Diabetologia, 2014, 57, 1720-1725.	6.3	56
365	Transcriptional and Functional Characterization of the G Protein-Coupled Receptor Repertoire of Gastric Somatostatin Cells. Endocrinology, 2015, 156, 3909-3923.	2.8	56
366	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E505-E514.	3.5	56
367	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides, 2018, 100, 173-181.	2.4	56
368	Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. European Journal of Endocrinology, 2007, 156, 663-671.	3.7	55
369	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regulatory Peptides, 2007, 144, 123-130.	1.9	55
370	Immunoassays for the incretin hormones GIP and GLP-1. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 425-432.	4.7	55
371	Effects of meal size and composition on incretin, α-cell, and β-cell responses. Metabolism: Clinical and Experimental, 2010, 59, 502-511.	3.4	55
372	Exendin-4 and exendin-(9–39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7–36)NH2. European Journal of Pharmacology, 1994, 269, 183-191.	2.6	54
373	Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective. Biochemical and Biophysical Research Communications, 2002, 294, 1-4.	2.1	54
374	CIP-(3–42) does not antagonize insulinotropic effects of CIP at physiological concentrations. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E468-E475.	3.5	54
375	The effect of DPPâ€4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clinical Endocrinology, 2010, 73, 189-196.	2.4	54
376	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. Diabetes Care, 2017, 40, 109-116.	8.6	54
377	Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas. Journal of the Autonomic Nervous System, 1986, 17, 71-84.	1.9	53
378	Effects of Intravenous Glucagon-Like Peptide-1 on Glucose Control and Hemodynamics After Coronary Artery Bypass Surgery in Patients With Type 2 Diabetes. American Journal of Cardiology, 2008, 102, 646-647.	1.6	53

#	Article	IF	CITATIONS
379	GLP-1 Responses Are Heritable and Blunted in Acquired Obesity With High Liver Fat and Insulin Resistance. Diabetes Care, 2014, 37, 242-251.	8.6	53
380	Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. Journal of Diabetes and Its Complications, 2015, 29, 413-421.	2.3	53
381	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. EBioMedicine, 2016, 7, 112-120.	6.1	53
382	Effect of <scp>GLP</scp> â€1 receptor agonist treatment on body weight in obese antipsychoticâ€treated patients with schizophrenia: <scp>a</scp> randomized, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2017, 19, 162-171.	4.4	53
383	The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regulatory Peptides, 2006, 137, 168-172.	1.9	52
384	Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. European Journal of Endocrinology, 2013, 169, 421-430.	3.7	52
385	GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Peptides, 2014, 55, 52-57.	2.4	52
386	Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 354-363.	8.1	52
387	Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid) Tj ETC	2q110.78	4314 rgBT 0
388	Hyperglycemia Acutely Lowers the Postprandial Excursions of Glucagon-Like Peptide-1 and Gastric Inhibitory Polypeptide in Humans. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1379-1385.	3.6	51
389	Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes—The brain as a biosensor. Diabetes Research and Clinical Practice, 2010, 88, 22-28.	2.8	51
390	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. European Journal of Endocrinology, 2013, 169, 187-201.	3.7	51
391	GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E355-E362.	3.5	51
392	Gastrin-Releasing Peptide in the Porcine Pancreas. Gastroenterology, 1987, 92, 1153-1158.	1.3	50
393	Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut, 2013, 62, 1724-1733.	12.1	50
394	Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine Connections, 2014, 3, 11-16.	1.9	50
395	Resistant starch and protein intake enhances fat oxidation and feelings of fullness in lean and overweight/obese women. Nutrition Journal, 2015, 14, 113.	3.4	50
396	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. American Journal of Clinical Nutrition, 2015, 102, 600-607.	4.7	50

#	Article	IF	CITATIONS
397	Role of Glucagon in Catabolism and Muscle Wasting of Critical Illness and Modulation by Nutrition. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1131-1143.	5.6	50
398	Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. Diabetes Care, 2017, 40, 1522-1529.	8.6	50
399	Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. European Journal of Endocrinology, 2017, 177, 455-464.	3.7	50
400	Mechanisms Preserving Insulin Action during High Dietary Fat Intake. Cell Metabolism, 2019, 29, 50-63.e4.	16.2	50
401	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. Diabetes, 2020, 69, 1090-1099.	0.6	50
402	Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. Current Diabetes Reviews, 2009, 5, 266-275.	1.3	49
403	Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 57-62.	2.3	49
404	GLP-1 as a Mediator in the Remission of Type 2 Diabetes After Gastric Bypass and Sleeve Gastrectomy Surgery. Diabetes, 2014, 63, 3172-3174.	0.6	49
405	Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovascular Disorders, 2015, 15, 75.	1.7	49
406	Gut hormones as pharmaceuticals. Regulatory Peptides, 2000, 93, 45-51.	1.9	48
407	Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. European Journal of Gastroenterology and Hepatology, 2005, 17, 207-212.	1.6	48
408	K _{ATP} Channel Closure Ameliorates the Impaired Insulinotropic Effect of Glucose-Dependent Insulinotropic Polypeptide in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 603-608.	3.6	48
409	Glucagon-like peptide-2 induces rapid digestive adaptation following intestinal resection in preterm neonates. American Journal of Physiology - Renal Physiology, 2013, 305, G277-G285.	3.4	48
410	Effect of Liraglutide Treatment on Jejunostomy Output in Patients With Short Bowel Syndrome: An Open‣abel Pilot Study. Journal of Parenteral and Enteral Nutrition, 2018, 42, 112-121.	2.6	48
411	Comparison Of The Long-Term Effects Of Liraglutide And Glimepiride Monotherapy On Bone Mineral Density In Patients With Type 2 Diabetes. Endocrine Practice, 2016, 22, 406-411.	2.1	48
412	Genetic variation within the TRPM5 locus associates with prediabetic phenotypes in subjects at increased risk for type 2 diabetes. Metabolism: Clinical and Experimental, 2011, 60, 1325-1333.	3.4	47
413	Continuous Parenteral and Enteral Nutrition Induces Metabolic Dysfunction in Neonatal Pigs. Journal of Parenteral and Enteral Nutrition, 2012, 36, 538-550.	2.6	47
414	Use of anesthesia dramatically alters the oral glucose tolerance and insulin secretion in C57Bl/6 mice. Physiological Reports, 2016, 4, e12824.	1.7	47

#	Article	IF	CITATIONS
415	Nervous control of pancreatic endocrine secretion in pigs. Acta Physiologica Scandinavica, 1981, 111, 1-7.	2.2	46
416	Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R1175-R1184.	1.8	46
417	Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. Diabetes Therapy, 2012, 3, 10.	2.5	46
418	The l-α-amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in l-arginine-induced insulin release. Amino Acids, 2013, 44, 383-390.	2.7	46
419	In vivo and in vitro degradation of peptide YY _{3–36} to inactive peptide YY _{3–34} in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R866-R874.	1.8	46
420	Glucose-Dependent Insulinotropic Polypeptide Is Associated With Lower Low-Density Lipoprotein But Unhealthy Fat Distribution, Independent of Insulin: The ADDITION-PRO Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 485-493.	3.6	46
421	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. Diabetes Care, 2016, 39, 617-624.	8.6	46
422	An atlas of O-linked glycosylation on peptide hormones reveals diverse biological roles. Nature Communications, 2020, 11, 4033.	12.8	46
423	Effect of wheat bran derived prebiotic supplementation on gastrointestinal transit, gut microbiota, and metabolic health: a randomized controlled trial in healthy adults with a slow gut transit. Gut Microbes, 2020, 12, 1704141.	9.8	46
424	Genetic determinants of circulating GIP and GLP-1 concentrations. JCI Insight, 2017, 2, .	5.0	46
425	Release of PYY from pig intestinal mucosa; luminal and neural regulation. Regulatory Peptides, 1989, 26, 253-266.	1.9	45
426	Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. American Journal of Physiology - Renal Physiology, 2009, 297, G861-G868.	3.4	45
427	Effect of Glucagon-Like Peptide-1 on α- and β-Cell Function in C-Peptide-Negative Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2492-2496.	3.6	45
428	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. American Journal of Physiology - Renal Physiology, 2016, 310, G43-G51.	3.4	45
429	GLP-2 and GIP exert separate effects on bone turnover: A randomized, placebo-controlled, crossover study in healthy young men. Bone, 2019, 125, 178-185.	2.9	45
430	Galanin in the porcine pancreas. Regulatory Peptides, 1990, 28, 161-176.	1.9	44
431	Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism: Clinical and Experimental, 2009, 58, 586-593.	3.4	44
432	Dipeptidyl peptidase expression during experimental colitis in mice. Inflammatory Bowel Diseases, 2010, 16, 1340-1351.	1.9	44

#	Article	IF	CITATIONS
433	The glycemic, insulinemic and plasma amino acid responses to equi-carbohydrate milk meals, a pilot- study of bovine and human milk. Nutrition Journal, 2012, 11, 83.	3.4	44
434	Examining the Effects of Hyperglycemia on Pancreatic Endocrine Function in Humans: Evidence for <i>in Vivo</i> Glucotoxicity. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4682-4691.	3.6	44
435	Normal physical activity obliterates the deleterious effects of a high-caloric intake. Journal of Applied Physiology, 2014, 116, 231-239.	2.5	44
436	Proglucagon Processing Profile in Canine L Cells Expressing Endogenous Prohormone Convertase 1/3 and Prohormone Convertase 2. Endocrinology, 1999, 140, 4800-4808.	2.8	43
437	Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism: Clinical and Experimental, 2003, 52, 1579-1585.	3.4	43
438	Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. American Journal of Clinical Nutrition, 2006, 84, 1142-1150.	4.7	43
439	Intestinal Permeability and Glucagon-like peptide-2 in Children with Autism: A Controlled Pilot Study. Journal of Autism and Developmental Disorders, 2008, 38, 1066-1071.	2.7	43
440	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. American Journal of Physiology - Renal Physiology, 2013, 304, G413-G419.	3.4	43
441	Incretin Effect and Glucagon Responses to Oral and Intravenous Glucose in Patients With Maturity-Onset Diabetes of the YoungType 2 and Type 3. Diabetes, 2014, 63, 2838-2844.	0.6	43
442	Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. American Journal of Clinical Nutrition, 2015, 101, 870-878.	4.7	43
443	Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist. Diabetes, 2016, 65, 2440-2447.	0.6	43
444	Hemodynamic Effects of Glucagon: A Literature Review. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1804-1812.	3.6	43
445	The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones. Molecular Metabolism, 2019, 19, 49-64.	6.5	43
446	The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology, 2021, 162, .	2.8	43
447	Reflex adrenergic control of endocrine pancreas evoked by unloading of carotid baroreceptors in cats. Acta Physiologica Scandinavica, 1978, 104, 188-202.	2.2	42
448	Effects of gastric emptying on the postprandial ghrelin response. American Journal of Physiology - Endocrinology and Metabolism, 2006, 290, E389-E395.	3.5	42
449	The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 410-419.	1.2	42
450	Bile acids drive colonic secretion of glucagon-like-peptide 1 and peptide-YY in rodents. American Journal of Physiology - Renal Physiology, 2019, 316, G574-G584.	3.4	42

#	Article	IF	CITATIONS
451	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1064-e1074.	3.6	42
452	Secretory effects of cholecystokinins on the isolated perfused porcine pancreas. Acta Physiologica Scandinavica, 1981, 111, 225-231.	2.2	41
453	The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects. Clinical Endocrinology, 1998, 49, 589-595.	2.4	41
454	GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regulatory Peptides, 2002, 107, 129-135.	1.9	41
455	Exogenous Glucagonâ€Like Peptideâ€2 (GLPâ€2) Augments GLPâ€2 Receptor mRNA and Maintains Proglucagon mRNA Levels in Resected Rats. Journal of Parenteral and Enteral Nutrition, 2008, 32, 254-265.	2.6	41
456	Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. Journal of Gastroenterology, 2013, 48, 322-332.	5.1	41
457	Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone, 2017, 97, 261-266.	2.9	41
458	Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E224-E233.	3.5	41
459	Inhibiting RHOA Signaling in Mice Increases Glucose Tolerance and Numbers of Enteroendocrine and Other Secretory Cells in the Intestine. Gastroenterology, 2018, 155, 1164-1176.e2.	1.3	41
460	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2953-2960.	3.6	41
461	Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People. Diabetes Care, 2020, 43, 411-417.	8.6	41
462	Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. American Journal of Physiology - Renal Physiology, 2007, 293, G288-G295.	3.4	40
463	Incretin-Based Therapy of Type 2 Diabetes Mellitus. Current Protein and Peptide Science, 2009, 10, 46-55.	1.4	40
464	Effect of growth in infancy on body composition, insulin resistance, and concentration of appetite hormones in adolescence. American Journal of Clinical Nutrition, 2010, 91, 1675-1683.	4.7	40
465	Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 2146-2152.	4.3	40
466	Glutamate prevents intestinal atrophy <i>via</i> luminal nutrient sensing in a mouse model of total parenteral nutrition. FASEB Journal, 2014, 28, 2073-2087.	0.5	40
467	The glucagon-like peptide 2 receptor is expressed in enteric neurons and not in the epithelium of the intestine. Peptides, 2015, 67, 20-28.	2.4	40
468	Oxygen supply, oxygen consumption, and endocrine and exocrine secretions of the isolated, perfused, porcine pancreas. Acta Physiologica Scandinavica, 1980, 109, 7-13.	2.2	39

#	Article	IF	CITATIONS
469	The intestinal mucosa preferentially releases somatostatin-28 in pigs. Regulatory Peptides, 1985, 11, 251-262.	1.9	39
470	Early detection of response in small cell bronchogenic carcinoma by changes in serum concentrations of creatine kinase, neuron specific enolase, calcitonin, ACTH, serotonin and gastrin releasing peptide. European Journal of Cancer & Clinical Oncology, 1988, 24, 1033-1038.	0.7	39
471	Insulin Secretion and Cellular Glucose Metabolism after Prolonged Low-Grade Intralipid Infusion in Young Men. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2775-2783.	3.6	39
472	No Hypoglycemia After Subcutaneous Administration of Glucagon-Like Peptide-1 in Lean Type 2 Diabetic Patients and in Patients With Diabetes Secondary to Chronic Pancreatitis. Diabetes Care, 2003, 26, 2581-2587.	8.6	39
473	Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regulatory Peptides, 2004, 118, 89-97.	1.9	39
474	Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scandinavian Journal of Gastroenterology, 2008, 43, 1304-1310.	1.5	39
475	Glucagon-Like Peptide-1 Inhibits Blood-Brain Glucose Transfer in Humans. Diabetes, 2008, 57, 325-331.	0.6	39
476	A Low Glycemic Index Diet Does Not Affect Postprandial Energy Metabolism but Decreases Postprandial Insulinemia and Increases Fullness Ratings in Healthy Women. Journal of Nutrition, 2011, 141, 1679-1684.	2.9	39
477	Why is it so difficult to measure glucagon-like peptide-1 in a mouse?. Diabetologia, 2017, 60, 2066-2075.	6.3	39
478	A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients. British Journal of Nutrition, 2018, 119, 910-917.	2.3	39
479	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 313-324.	11.4	39
480	Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scandinavian Journal of Gastroenterology, 2006, 41, 667-672.	1.5	38
481	Meal-Stimulated Glucagon Release Is Associated with Postprandial Blood Glucose Level and Does Not Interfere with Glycemic Control in Children and Adolescents with New-Onset Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2910-2916.	3.6	38
482	GLPâ€2 Administration Results in Increased Proliferation but Paradoxically an Adverse Outcome in a Juvenile Piglet Model of Short Bowel Syndrome. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 20-28.	1.8	38
483	Is there a place for incretin therapies in obesity and prediabetes?. Trends in Endocrinology and Metabolism, 2013, 24, 145-152.	7.1	38
484	Gastric emptying and disease activity in inflammatory bowel disease. European Journal of Clinical Investigation, 2015, 45, 1234-1242.	3.4	38
485	Physiology of the Incretin Hormones, <scp>GIP</scp> and <scp>GLP</scp> â€1—Regulation of Release and Posttranslational Modifications. , 2019, 9, 1339-1381.		38
486	Methods and Guidelines for Measurement of Glucagon in Plasma. International Journal of Molecular Sciences, 2019, 20, 5416.	4.1	38

#	Article	IF	CITATIONS
487	Postprandial hypoglycaemia after Rouxâ€en‥ gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. Diabetes, Obesity and Metabolism, 2019, 21, 2142-2151.	4.4	38
488	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. Diabetes Care, 2020, 43, 588-596.	8.6	38
489	Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes. PLoS ONE, 2013, 8, e73154.	2.5	38
490	Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate. Scandinavian Journal of Gastroenterology, 2007, 42, 814-820.	1.5	37
491	Glucagon and Glucagon-Like Peptides 1 and 2. Results and Problems in Cell Differentiation, 2009, 50, 221-234.	0.7	37
492	Transgenic Rescue of Adipocyte Glucose-dependent Insulinotropic Polypeptide Receptor Expression Restores High Fat Diet-induced Body Weight Gain. Journal of Biological Chemistry, 2011, 286, 44632-44645.	3.4	37
493	Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal. American Journal of Clinical Nutrition, 2011, 94, 967-972.	4.7	37
494	Intestinal Adaptation Is Stimulated by Partial Enteral Nutrition Supplemented With the Prebiotic Shortâ€Chain Fructooligosaccharide in a Neonatal Intestinal Failure Piglet Model. Journal of Parenteral and Enteral Nutrition, 2012, 36, 524-537.	2.6	37
495	Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemotherapy and Pharmacology, 2012, 70, 39-48.	2.3	37
496	Therapies for inter-relating diabetes and obesity – GLP-1 and obesity. Expert Opinion on Pharmacotherapy, 2014, 15, 2487-2500.	1.8	37
497	Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia, 2016, 59, 363-370.	6.3	37
498	Regulation of gut hormone secretion. Studies using isolated perfused intestines. Peptides, 2016, 77, 47-53.	2.4	37
499	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e725-e738.	3.6	37
500	Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trial. Diabetologia, 2022, 65, 506-517.	6.3	37
501	Peptoneâ€mediated glucagonâ€like peptideâ€1 secretion depends on intestinal absorption and activation of basolaterally located Calciumâ€5ensing Receptors. Physiological Reports, 2019, 7, e14056.	1.7	36
502	Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys. Psychopharmacology, 2019, 236, 603-611.	3.1	36
503	Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, .	0.5	36
504	Somatostatin 1–28 circulates in human plasma. Regulatory Peptides, 1983, 6, 63-69.	1.9	35

#	Article	IF	CITATIONS
505	Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 1910-1914.	8.6	35
506	The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib. Clinical Cancer Research, 2007, 13, 5170-5175.	7.0	35
507	GLP1- and GIP-producing cells rarely overlap and differ by bombesin receptor-2 expression and responsiveness. Journal of Endocrinology, 2016, 228, 39-48.	2.6	35
508	Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches. Biology, 2020, 9, 473.	2.8	35
509	Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opinion on Emerging Drugs, 2004, 9, 155-166.	2.4	35
510	Inhibition of human pancreatic and biliary output but not intestinal motility by physiological intraileal lipid loads. American Journal of Physiology - Renal Physiology, 2006, 290, G704-G709.	3.4	34
511	The T-Allele of TCF7L2 rs7903146 Associates With a Reduced Compensation of Insulin Secretion for Insulin Resistance Induced by 9 Days of Bed Rest. Diabetes, 2010, 59, 836-843.	0.6	34
512	Postprandial Insulin Secretion After Gastric Bypass Surgery. Diabetes, 2011, 60, 2203-2205.	0.6	34
513	Impaired Crosstalk between Pulsatile Insulin and Glucagon Secretion in Prediabetic Individuals. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E791-E795.	3.6	34
514	Glucose stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1 and GLUT2, leading to cell depolarization and calcium influx. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E1123-E1130.	3.5	34
515	Integrative Genomics Outlines a Biphasic Glucose Response and a ChREBP-RORÎ ³ Axis Regulating Proliferation in Î ² Cells. Cell Reports, 2016, 16, 2359-2372.	6.4	34
516	Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E302-E309.	3.5	34
517	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6403-6416.	3.6	34
518	Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Human Reproduction, 2022, 37, 1414-1422.	0.9	34
519	Simultaneous recording of the gastro-entero-pancreatic hormonal peptide response to food in man. Metabolism: Clinical and Experimental, 1980, 29, 777-779.	3.4	33
520	Potential targets for glucagon-like peptide 2 (GLP-2) in the rat: distribution and binding of i.v. injected 1251-GLP-2. Peptides, 2000, 21, 1511-1517.	2.4	33
521	Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E431-E438.	3.5	33
522	Plasma GLP-2 Levels and Intestinal Markers in the Juvenile Pig During Intestinal Adaptation: Effects of Different Diet Regimens. Digestive Diseases and Sciences, 2004, 49, 1688-1695.	2.3	33

#	Article	IF	CITATIONS
523	Evidence of an Association Between the Arg72 Allele of the Peptide YY and Increased Risk of Type 2 Diabetes. Diabetes, 2005, 54, 2261-2265.	0.6	33
524	Delayed β-cell response and glucose intolerance in young women with Turner syndrome. BMC Endocrine Disorders, 2011, 11, 6.	2.2	33
525	Hypoglycemia-Associated Changes in the Electroencephalogram in Patients With Type 1 Diabetes and Normal Hypoglycemia Awareness or Unawareness. Diabetes, 2015, 64, 1760-1769.	0.6	33
526	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. Journal of Diabetes Research, 2016, 2016, 1-5.	2.3	33
527	Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3155-3162.	3.6	33
528	Patients With Long-QT Syndrome Caused by Impaired <i>hERG</i> -Encoded K _v 11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia. Circulation, 2017, 135, 1705-1719.	1.6	33
529	The bile acidâ€sequestering resin sevelamer eliminates the acute <scp>GLP</scp> â€1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 362-369.	4.4	33
530	Using a Reporter Mouse to Map Known and Novel Sites of GLP-1 Receptor Expression in Peripheral Tissues of Male Mice. Endocrinology, 2021, 162, .	2.8	33
531	The effect of gastrin on basal and aminoacid-stimulated insulin and glucagon secretion in man. European Journal of Clinical Investigation, 1978, 8, 5-9.	3.4	32
532	Galanin and Galanin Extended at the N-Terminus with Seven and Nine Amino Acids Are Produced in and Secreted from the Porcine Adrenal Medulla in almost Equal Amounts*. Endocrinology, 1991, 129, 2693-2698.	2.8	32
533	Differential regional metabolism of glucagon in anesthetized pigs. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E552-E560.	3.5	32
534	Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic β-cells. European Journal of Endocrinology, 2005, 152, 103-112.	3.7	32
535	Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus. Gynecological Endocrinology, 2007, 23, 58-62.	1.7	32
536	Functional Ontogeny of the Proglucagon-Derived Peptide Axis in the Premature Human Neonate. Pediatrics, 2008, 121, e180-e186.	2.1	32
537	Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract. Scandinavian Journal of Gastroenterology, 2008, 43, 929-937.	1.5	32
538	Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. Biochemical and Biophysical Research Communications, 2010, 393, 410-413.	2.1	32
539	The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters. Regulatory Peptides, 2010, 159, 67-71.	1.9	32
540	Rapid gut growth but persistent delay in digestive function in the postnatal period of preterm pigs. American Journal of Physiology - Renal Physiology, 2016, 310, G550-G560.	3.4	32

#	Article	IF	CITATIONS
541	Chenodeoxycholic acid stimulates glucagonâ€like peptideâ€1 secretion in patients after Rouxâ€enâ€Y gastric bypass. Physiological Reports, 2017, 5, e13140.	1.7	32
542	Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 575-585.	3.6	32
543	Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E1081-E1093.	3.5	32
544	Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia. Obesity Surgery, 2019, 29, 2092-2099.	2.1	32
545	Alanine, arginine, cysteine, and proline, but not glutamine, are substrates for, and acute mediators of, the liver-α-cell axis in female mice. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E920-E929.	3.5	32
546	Nervous control of pancreatic endocrine secretion in pigs. Acta Physiologica Scandinavica, 1981, 111, 9-14.	2.2	31
547	Pancreastatin-Like Immunoreactivity and Insulin are Released in Parallel from the Perfused Porcine Pancreas. Endocrinology, 1989, 124, 2986-2990.	2.8	31
548	Somatostatin and prosomatostatin in the retina of the rat: An immunohistochemical, in-situ hybridization, and chromatographic study. Visual Neuroscience, 1990, 5, 441-452.	1.0	31
549	Somatostatin Is an Essential Paracrine Link in Acid Inhibition of Gastrin Secretion. Digestion, 1992, 51, 95-102.	2.3	31
550	Inhibition of human gastric lipase secretion by glucagon-like peptide-1. Digestive Diseases and Sciences, 1998, 43, 799-805.	2.3	31
551	Secretion of Trophic Gut Peptides Is Not Different in Bolus- and Continuously Fed Piglets. Journal of Nutrition, 2001, 131, 729-732.	2.9	31
552	Implementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors. , 2003, 524, 263-279.		31
553	Normal Secretion and Action of the Gut Incretin Hormones Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Young Men with Low Birth Weight. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4912-4919.	3.6	31
554	Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. European Journal of Endocrinology, 2010, 162, 75-83.	3.7	31
555	Sex Steroids Affect Triglyceride Handling, Glucose-Dependent Insulinotropic Polypeptide, and Insulin Sensitivity. Diabetes Care, 2010, 33, 1831-1833.	8.6	31
556	Do the Actions of Glucagon-Like Peptide-1 on Gastric Emptying, Appetite, and Food Intake Involve Release of Amylin in Humans?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2367-2375.	3.6	31
557	Gastric Emptying of Orally Administered Glucose Solutions and Incretin Hormone Responses Are Unaffected by Laparoscopic Adjustable Gastric Banding. Obesity Surgery, 2011, 21, 625-632.	2.1	31
558	Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2457-2466.	3.6	31

#	Article	IF	CITATIONS
559	Glucagon-like peptide-1 does not have acute effects on central or renal hemodynamics in patients with type 2 diabetes without nephropathy. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E744-E753.	3.5	31
560	The regulation of function, growth and survival of GLP-1-producing L-cells. Clinical Science, 2016, 130, 79-91.	4.3	31
561	Semaglutide seems to be more effective the other GLP-1Ras. Annals of Translational Medicine, 2017, 5, 505-505.	1.7	31
562	Glucagonâ€like peptideâ€1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. Physiological Reports, 2017, 5, e13073.	1.7	31
563	In the rat pancreas, somatostatin tonically inhibits glucagon secretion and is required for glucoseâ€induced inhibition of glucagon secretion. Acta Physiologica, 2020, 229, e13464.	3.8	31
564	Sympathoadrenal Regulation of Adrenal Androstenedione Release. Neuroendocrinology, 1994, 59, 406-412.	2.5	30
565	The structure of wheat bread influences the postprandial metabolic response in healthy men. Food and Function, 2015, 6, 3236-3248.	4.6	30
566	Searching for the physiological role of glucoseâ€dependent insulinotropic polypeptide. Journal of Diabetes Investigation, 2016, 7, 8-12.	2.4	30
567	PACAP contributes to insulin secretion after gastric glucose gavage in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2000, 279, R424-R432.	1.8	29
568	Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 295, R1794-R1802.	1.8	29
569	Temporal Changes in the Intestinal Growth Promoting Effects of Glucagon-Like Peptide 2 Following Intestinal Resection. Journal of Surgical Research, 2009, 152, 271-280.	1.6	29
570	Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2012, 32, 1-14.	2.2	29
571	Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney International, 2013, 83, 915-923.	5.2	29
572	Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regulatory Peptides, 2014, 188, 70-80.	1.9	29
573	Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition. Cellular and Molecular Gastroenterology and Hepatology, 2017, 3, 447-468.	4.5	29
574	On the relationship between glucose absorption and glucoseâ€stimulated secretion of <scp>GLP</scp> â€1, neurotensin, and <scp>PYY</scp> from different intestinal segments in the rat. Physiological Reports, 2017, 5, e13507.	1.7	29
575	Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion. Nutrients, 2017, 9, 418.	4.1	29
576	Extracellular Fluid Volume Expansion Uncovers a Natriuretic Action of GLP-1: A Functional GLP-1–Renal Axis in Man. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2509-2519.	3.6	29

#	Article	IF	CITATIONS
577	Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. Surgery, 2011, 150, 217-223.	1.9	28
578	Appetite regulation in overweight, sedentary men after different amounts of endurance exercise: a randomized controlled trial. Journal of Applied Physiology, 2013, 115, 1599-1609.	2.5	28
579	Relationships among tonic and episodic aspects of motivation to eat, gut peptides, and weight before and after bariatric surgery. Surgery for Obesity and Related Diseases, 2013, 9, 802-808.	1.2	28
580	Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure. Regulatory Peptides, 2013, 181, 4-8.	1.9	28
581	Removal of Duodenum Elicits GLP-1 Secretion. Diabetes Care, 2013, 36, 1641-1646.	8.6	28
582	Effects of hydrolysed casein, intact casein and intact whey protein on energy expenditure and appetite regulation: a randomised, controlled, cross-over study. British Journal of Nutrition, 2014, 112, 1412-1422.	2.3	28
583	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. Cell Reports, 2017, 21, 1452-1460.	6.4	28
584	Addition of a dipeptidyl peptidaseâ€4 inhibitor, sitagliptin, to ongoing therapy with the glucagonâ€like peptideâ€1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 200-207.	4.4	28
585	Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: <scp>A</scp> randomized, placeboâ€controlled, doubleâ€blind, parallelâ€group study. Diabetes, Obesity and Metabolism, 2017, 19, 773-782	4.4	28
586	Glucagonâ€like peptideâ€1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLPâ€1 receptors. Physiological Reports, 2017, 5, e13503.	1.7	28
587	Paracrine regulation of somatostatin secretion by insulin and glucagon in mouse pancreatic islets. Diabetologia, 2021, 64, 142-151.	6.3	28
588	Nervous control of the release of substance P and neurokinin A from the isolated perfused porcine ileum. Journal of the Autonomic Nervous System, 1992, 38, 85-95.	1.9	27
589	Tachykinins in the Porcine Pancreas: Potent Exocrine and Endocrine Effects Via NK-1 Receptors. Pancreas, 2000, 20, 241-247.	1.1	27
590	1,5-Anhydro-d-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice. European Journal of Pharmacology, 2000, 397, 219-225.	3.5	27
591	Impaired Glucose-Induced Glucagon Suppression after Partial Pancreatectomy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2857-2863.	3.6	27
592	Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. Scandinavian Journal of Gastroenterology, 2011, 46, 428-435.	1.5	27
593	Preoperative βâ€cell function in patients with type 2 diabetes is important for the outcome of Rouxâ€enâ€Y gastric bypass surgery. Journal of Physiology, 2015, 593, 3123-3133.	2.9	27
594	Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. Diabetologia, 2015, 58, 920-928.	6.3	27

#	Article	IF	CITATIONS
595	Single-Dose Metformin Enhances Bile Acid–Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4153-4162.	3.6	27
596	Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. International Journal of Obesity, 2019, 43, 1009-1018.	3.4	27
597	Biliopancreatic diversion with duodenal switch (BPD-DS) and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) result in distinct post-prandial hormone profiles. International Journal of Obesity, 2019, 43, 2518-2527.	3.4	27
598	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2020, 318, G661-G672.	3.4	27
599	Nervous control of pancreatic endocrine secretion in pigs. Acta Physiologica Scandinavica, 1981, 111, 15-22.	2.2	26
600	Glucagon-like peptide-1: physiology and therapeutic potential. Current Opinion in Endocrinology, Diabetes and Obesity, 2005, 12, 56-62.	0.6	26
601	Porcine glucagon-like peptide-2: Structure, signaling, metabolism and effects. Regulatory Peptides, 2008, 146, 310-320.	1.9	26
602	No increased risk of hypoglycaemic episodes during 48Âh of subcutaneous glucagonâ€likeâ€peptideâ€1 administration in fasting healthy subjects. Clinical Endocrinology, 2009, 71, 500-506.	2.4	26
603	GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes. Diabetes Research and Clinical Practice, 2009, 85, 1-3.	2.8	26
604	The Intestinotrophic Peptide, GLP-2, Counteracts the Gastrointestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, and Cisplatin. Digestive Diseases and Sciences, 2010, 55, 2785-2796.	2.3	26
605	Islet-cell dysfunction induced by glucocorticoid treatment: potential role for altered sympathovagal balance?. Metabolism: Clinical and Experimental, 2013, 62, 568-577.	3.4	26
606	Lactobacillus paracasei subsp paracasei L. casei W8 suppresses energy intake acutely. Appetite, 2014, 82, 111-118.	3.7	26
607	Gut: A key player in the pathogenesis of type 2 diabetes?. Critical Reviews in Food Science and Nutrition, 2018, 58, 1294-1309.	10.3	26
608	Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E660-E673.	3.5	26
609	Predictors of weight loss after bariatric surgery—a cross-disciplinary approach combining physiological, social, and psychological measures. International Journal of Obesity, 2020, 44, 2291-2302.	3.4	26
610	The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels. Diabetologia, 2021, 64, 512-520.	6.3	26
611	Differential Postprandial Lipoprotein Responses in Type 2 Diabetic Men with and without Clinical Evidence of a Former Myocardial Infarction. Review of Diabetic Studies, 2004, 1, 175-175.	1.3	26
612	The incretin/glucagon system as a target for pharmacotherapy of obesity. Obesity Reviews, 2022, 23, .	6.5	26

#	Article	IF	CITATIONS
613	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs: the Investigational Drugs Journal, 2009, 12, 503-13.	0.7	26
614	The Liver–α-Cell Axis in Health and in Disease. Diabetes, 2022, 71, 1852-1861.	0.6	26
615	Nervous control of pancreatic endocrine secretion in pigs V. Influence of the sympathetic nervous system on the pancreatic secretion of insulin and glucagon, and on the insulin and glucagon response to vagal stimulation. Acta Physiologica Scandinavica, 1981, 113, 279-283.	2.2	25
616	PACAP 1–38 as neurotransmitter in the porcine antrum. Regulatory Peptides, 2001, 101, 109-121.	1.9	25
617	Orlistat accelerates gastric emptying and attenuates CIP release in healthy subjects. American Journal of Physiology - Renal Physiology, 2009, 296, G482-G489.	3.4	25
618	Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Experimental Dermatology, 2013, 22, 150-152.	2.9	25
619	Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain. Frontiers in Neuroenergetics, 2013, 5, 2.	5.3	25
620	Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. European Journal of Nutrition, 2017, 56, 1063-1076.	3.9	25
621	Non-insulin pharmacological therapies for treating type 1 diabetes. Expert Opinion on Pharmacotherapy, 2018, 19, 947-960.	1.8	25
622	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Bone, 2020, 140, 115553.	2.9	25
623	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. International Journal of Obesity, 2020, 44, 1859-1871.	3.4	25
624	Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E874-E885.	3.5	25
625	Comparative analysis of oral and intraperitoneal glucose tolerance tests in mice. Molecular Metabolism, 2022, 57, 101440.	6.5	25
626	Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. European Journal of Endocrinology, 1988, 117, 302-306.	3.7	24
627	Role of gastrin-releasing peptide in the neural control of pepsinogen secretion from the pig stomach. Gastroenterology, 1988, 95, 1216-1220.	1.3	24
628	On the Treatment of Diabetes Mellitus with Glucagon-like Peptide-1. Annals of the New York Academy of Sciences, 1998, 865, 336-343.	3.8	24
629	Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients. Metabolism: Clinical and Experimental, 2004, 53, 77-83.	3.4	24
630	Targeting the intestinal L-cell for obesity and type 2 diabetes treatment. Expert Review of Endocrinology and Metabolism, 2014, 9, 61-72.	2.4	24

#	Article	IF	CITATIONS
631	Bile acid mediated effects on gut integrity and performance of early-weaned piglets. BMC Veterinary Research, 2015, 11, 111.	1.9	24
632	Updates in weight loss surgery and gastrointestinal peptides. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 21-28.	2.3	24
633	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	3.6	24
634	The impact of <scp>EndoBarrier</scp> gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 189-199.	4.4	24
635	Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women. European Journal of Endocrinology, 2019, 180, 417-427.	3.7	24
636	GLP-1 Val8: A Biased GLP-1R Agonist with Altered Binding Kinetics and Impaired Release of Pancreatic Hormones in Rats. ACS Pharmacology and Translational Science, 2021, 4, 296-313.	4.9	24
637	The effect of gastrin-releasing peptide on the endocrine pancreas. Regulatory Peptides, 1987, 17, 269-276.	1.9	23
638	PACAP-(1–38) as neurotransmitter in the porcine adrenal glands. American Journal of Physiology - Endocrinology and Metabolism, 2000, 279, E1413-E1425.	3.5	23
639	Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of β-cells. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E677-E685.	3.5	23
640	The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2008, 10, 14-21.	4.4	23
641	The effects of variations in dose and method of administration on glucagon like peptide-2 activity in the rat. European Journal of Pharmacology, 2008, 596, 138-145.	3.5	23
642	The Effect of PCSK1 Variants on Waist, Waist-Hip Ratio and Glucose Metabolism Is Modified by Sex and Glucose Tolerance Status. PLoS ONE, 2011, 6, e23907.	2.5	23
643	Alcohol Intake and Its Effect on Some Appetite-Regulating Hormones in Man: Influence of Gastroprotection with Sucralfate. Endocrine Research, 2012, 37, 154-162.	1.2	23
644	The anorexic hormone Peptide YY ₃₋₃₆ is rapidly metabolized to inactive Peptide YY ₃₋₃₄ inÂvivo. Physiological Reports, 2015, 3, e12455.	1.7	23
645	Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. Obesity Facts, 2017, 10, 633-647.	3.4	23
646	Health care professionals from developing countries report educational benefits after an online diabetes course. BMC Medical Education, 2017, 17, 97.	2.4	23
647	Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. PLoS ONE, 2018, 13, e0198046.	2.5	23
648	The imprinted gene Delta like non-canonical notch ligand 1 (Dlk1) associates with obesity and triggers insulin resistance through inhibition of skeletal muscle glucose uptake. EBioMedicine, 2019, 46, 368-380.	6.1	23

#	Article	IF	CITATIONS
649	Consumption of nutrients and insulin resistance suppress markers of bone turnover in subjects with abdominal obesity. Bone, 2020, 133, 115230.	2.9	23
650	Localization in the gastrointestinal tract of immunoreactive prosomatostatin. Regulatory Peptides, 1987, 19, 183-195.	1.9	22
651	The effect of salatrim, a low-calorie modified triacylglycerol, on appetite and energy intake. American Journal of Clinical Nutrition, 2008, 87, 1163-1169.	4.7	22
652	Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure. American Journal of Physiology - Renal Physiology, 2010, 299, G1222-G1230.	3.4	22
653	Bile Acids Induce Glucagon-Like Peptide 2 Secretion with Limited Effects on Intestinal Adaptation in Early Weaned Pigs. Journal of Nutrition, 2013, 143, 1899-1905.	2.9	22
654	High saturated fatty acid intake induces insulin secretion by elevating gastric inhibitory polypeptide levels in healthy individuals. Nutrition Research, 2014, 34, 653-660.	2.9	22
655	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 309, R544-R551.	1.8	22
656	Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes. Cell Reports, 2016, 17, 2845-2856.	6.4	22
657	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. Metabolic Syndrome and Related Disorders, 2018, 16, 530-536.	1.3	22
658	Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. American Journal of Clinical Nutrition, 2019, 110, 296-304.	4.7	22
659	Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). Diabetes Care, 2020, 43, 2025-2033.	8.6	22
660	Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis. Hepatology Communications, 2020, 4, 1610-1623.	4.3	22
661	Changes in the Homeostatic Appetite System After Weight Loss Reflect a Normalization Toward a Lower Body Weight. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2538-e2546.	3.6	22
662	Fasting Plasma GLP-1 Is Associated With Overweight/Obesity and Cardiometabolic Risk Factors in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1718-1727.	3.6	22
663	Effect of Fecal Microbiota Transplantation Combined With Mediterranean Diet on Insulin Sensitivity in Subjects With Metabolic Syndrome. Frontiers in Microbiology, 2021, 12, 662159.	3.5	22
664	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. Frontiers in Endocrinology, 2021, 12, 694284.	3.5	22
665	Actions of glucagonâ€like peptideâ€1 receptor ligands in the gut. British Journal of Pharmacology, 2022, 179, 727-742.	5.4	22
666	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. Cell Reports Medicine, 2020, 1, 100006.	6.5	22

#	Article	IF	CITATIONS
667	Influence of Erythropoietin on Cognitive Performance during Experimental Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Randomized Cross-Over Trial. PLoS ONE, 2013, 8, e59672.	2.5	22
668	Human colon produces fully processed glucagon-like peptide-1 (7-36) amide. FEBS Letters, 1995, 372, 269-272.	2.8	21
669	Gastric Inhibitory Polypeptide Analogues. BioDrugs, 2002, 16, 175-181.	4.6	21
670	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 453-462.	4.7	21
671	Gastric emptying, glucose metabolism and gut hormones: Evaluation of a common preoperative carbohydrate beverage. Nutrition, 2011, 27, 897-903.	2.4	21
672	Influence of GLP-1 on Myocardial Glucose Metabolism in Healthy Men during Normo- or Hypoglycemia. PLoS ONE, 2014, 9, e83758.	2.5	21
673	The influence of glucagon on postprandial hyperglycaemia in children 5Âyears after onset of type 1 diabetes. Diabetologia, 2015, 58, 828-834.	6.3	21
674	Inability to match energy intake with energy expenditure at sustained near-maximal rates of energy expenditure in older men during a 14-d cycling expedition. American Journal of Clinical Nutrition, 2015, 102, 1398-1405.	4.7	21
675	IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. Journal of Diabetes Science and Technology, 2016, 10, 389-397.	2.2	21
676	Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals. Diabetes Care, 2017, 40, 1314-1322.	8.6	21
677	Glucoseâ€lowering effects and mechanisms of the bile acidâ€sequestering resin sevelamer. Diabetes, Obesity and Metabolism, 2018, 20, 1623-1631.	4.4	21
678	Pre-Meal Effect of Whey Proteins on Metabolic Parameters in Subjects with and without Type 2 Diabetes: A Randomized, Crossover Trial. Nutrients, 2018, 10, 122.	4.1	21
679	Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats. Frontiers in Endocrinology, 2019, 10, 492.	3.5	21
680	Short-chain fatty acids and regulation of pancreatic endocrine secretion in mice. Islets, 2019, 11, 103-111.	1.8	21
681	Recent advances of GIP and future horizons. Peptides, 2020, 125, 170230.	2.4	21
682	Incretin therapy for diabetes mellitus type 2. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 2-10.	2.3	21
683	Effects of whey protein and dietary fiber intake on insulin sensitivity, body composition, energy expenditure, blood pressure, and appetite in subjects with abdominal obesity. European Journal of Clinical Nutrition, 2021, 75, 611-619.	2.9	21
684	Effects of endogenous GIP in patients with type 2 diabetes. European Journal of Endocrinology, 2021, 185, 33-45.	3.7	21

#	Article	IF	CITATIONS
685	Glycemic Effects and Safety of L-Glutamine Supplementation with or without Sitagliptin in Type 2 Diabetes Patients—A Randomized Study. PLoS ONE, 2014, 9, e113366.	2.5	21
686	LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Reports Medicine, 2022, 3, 100582.	6.5	21
687	Occurrence, Distribution and Motor Effects of Galanin in the Porcine Lower Esophageal Sphincter. Digestion, 1989, 42, 151-157.	2.3	20
688	Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7–36)amide in plasma. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 841-850.	2.8	20
689	Tumour necrosis factorâ€elpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. Diabetes/Metabolism Research and Reviews, 2013, 29, 655-663.	4.0	20
690	Evidence for paracrine/autocrine regulation of GLP-1-producing cells. American Journal of Physiology - Cell Physiology, 2013, 305, C1041-C1049.	4.6	20
691	Differential effects of glucagonâ€like peptideâ€1 on microvascular recruitment and glucose metabolism in short―and longâ€ŧerm insulin resistance. Journal of Physiology, 2015, 593, 2185-2198.	2.9	20
692	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3ÂYears After Gastric Bypass Surgery. Obesity Surgery, 2016, 26, 2263-2267.	2.1	20
693	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 908-915.	3.7	20
694	Effect of oral contraceptives and/or metformin on GLP-1 secretion and reactive hypoglycaemia in polycystic ovary syndrome. Endocrine Connections, 2017, 6, 267-277.	1.9	20
695	Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus. BMJ Open Diabetes Research and Care, 2017, 5, e000352.	2.8	20
696	GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3–30)NH2. Bone, 2020, 130, 115079.	2.9	20
697	Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness. Diabetes Care, 2021, 44, 224-230.	8.6	20
698	GLP-1 and Intestinal Diseases. Biomedicines, 2021, 9, 383.	3.2	20
699	Importance of colonic bacterial fermentation in short bowel patients: small intestinal malabsorption of easily digestible carbohydrate. Digestive Diseases and Sciences, 1999, 44, 1914-1923.	2.3	19
700	Treatment of adult short bowel syndrome patients with teduglutide. Expert Opinion on Pharmacotherapy, 2012, 13, 235-243.	1.8	19
701	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men. PLoS ONE, 2016, 11, e0145890.	2.5	19
702	Effects of a diet rich in arabinoxylan and resistant starch compared with a diet rich in refined carbohydrates on postprandial metabolism and features of the metabolic syndrome. European Journal of Nutrition, 2018, 57, 795-807.	3.9	19

#	Article	IF	CITATIONS
703	A Pilot Study Showing Acute Inhibitory Effect of GLPâ€l on the Bone Resorption Marker CTX in Humans. JBMR Plus, 2019, 3, e10209.	2.7	19
704	Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot doseâ€ranging study. Diabetes, Obesity and Metabolism, 2021, 23, 1311-1321.	4.4	19
705	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. Surgery for Obesity and Related Diseases, 2021, 17, 1383-1391.	1.2	19
706	Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients. Journal of Clinical Psychiatry, 2014, 75, e899-e905.	2.2	19
707	Does the Endocrine Secretion of the Pancreas Exert a Local Control of the Exocrine Secretion?. Pancreas, 1987, 2, 613-619.	1.1	18
708	Immunocytochemical localization and identification of prosomatostatin gene products in medullary carcinoma of human thyroid gland. Human Pathology, 1990, 21, 820-830.	2.0	18
709	The reduction in hepatic insulin clearance after oral glucose is not mediated by Gastric inhibitory polypeptide (GIP). Regulatory Peptides, 2003, 113, 95-100.	1.9	18
710	Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV. Regulatory Peptides, 2007, 138, 126-132.	1.9	18
711	Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2009, 58, 1809-1811.	3.4	18
712	Changes of cognition and regional cerebral activity during acute hypoglycemia in normal subjects: A H ₂ ¹⁵ O positron emission tomographic study. Journal of Neuroscience Research, 2009, 87, 1922-1928.	2.9	18
713	Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regulatory Peptides, 2010, 163, 96-101.	1.9	18
714	Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. American Journal of Physiology - Renal Physiology, 2012, 303, G610-G622.	3.4	18
715	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. Obesity Research and Clinical Practice, 2013, 7, e269-e274.	1.8	18
716	GLPâ€2 Delays but Does Not Prevent the Onset of Necrotizing Enterocolitis in Preterm Pigs. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 623-630.	1.8	18
717	The Effects of TNF-Î \pm on GLP-1-Stimulated Plasma Glucose Kinetics. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E616-E622.	3.6	18
718	Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3868-3876.	3.6	18
719	Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study. Diabetologia, 2019, 62, 582-592.	6.3	18
720	Oral <i>D/L-</i> 3-Hydroxybutyrate Stimulates Cholecystokinin and Insulin Secretion and Slows Gastric Emptying in Healthy Males. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3597-e3605.	3.6	18

#	Article	IF	CITATIONS
721	Endocrine and Metabolic Insights from Pancreatic Surgery. Trends in Endocrinology and Metabolism, 2020, 31, 760-772.	7.1	18
722	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. Diabetologia, 2020, 63, 1043-1054.	6.3	18
723	Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. BMJ Open Diabetes Research and Care, 2020, 8, e001076.	2.8	18
724	Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism. Journal of the Endocrine Society, 2021, 5, bvab084.	0.2	18
725	Associations between ghrelin and leptin and neural food cue reactivity in a fasted and sated state. NeuroImage, 2021, 240, 118374.	4.2	18
726	Extrinsic control of the release of galanin and VIP from intrinsic nerves of isolated, perfused, porcine ileum. Regulatory Peptides, 1992, 38, 179-198.	1.9	17
727	Release of immunoreactive somatostatin, vasoactive intestinal polypeptide (VIP), and galanin during propulsive complexes in isolated pig ileum. Peptides, 1993, 14, 215-220.	2.4	17
728	Gliclazide Directly Inhibits Arginine-Induced Glucagon Release. Diabetes, 2002, 51, S381-S384.	0.6	17
729	Neutral Endopeptidase 24.11 and Dipeptidyl Peptidase IV are Both Involved in Regulating the Metabolic Stability of Glucagon-like Peptide-1 in vivo. , 2003, 524, 303-312.		17
730	Glucagon-like peptide 2 has limited efficacy to increase nutrient absorption in fetal and preterm pigs. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R2179-R2184.	1.8	17
731	Colonic GLPâ€2 is not Sufficient to Promote Jejunal Adaptation in a PNâ€Dependent Rat Model of Human Short Bowel Syndrome. Journal of Parenteral and Enteral Nutrition, 2009, 33, 629-639.	2.6	17
732	Effects of Everyday Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion–Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. Diabetes Technology and Therapeutics, 2012, 14, 210-217.	4.4	17
733	L-Glutamine and Whole Protein Restore First-Phase Insulin Response and Increase Glucagon-Like Peptide-1 in Type 2 Diabetes Patients. Nutrients, 2015, 7, 2101-2108.	4.1	17
734	Sensing of triacylglycerol in the gut: different mechanisms for fatty acids and 2â€monoacylglycerol. Journal of Physiology, 2015, 593, 2097-2109.	2.9	17
735	Feedback suppression of mealâ€induced glucagonâ€like peptideâ€l (<scp>GLP</scp> â€l) secretion mediated through elevations in intact <scp>GLP</scp> â€l caused by dipeptidyl peptidaseâ€4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment. Diabetes, Obesity and Metabolism,	4.4	17
736	Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial. American Journal of Clinical Nutrition, 2016, 103, 435-443.	4.7	17
737	Atrial Natriuretic Peptide in the High Normal Range Is Associated With Lower Prevalence of Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1372-1380.	3.6	17
738	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scandinavian Journal of Gastroenterology, 2018, 53, 1429-1432.	1.5	17

#	Article	IF	CITATIONS
739	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4409-4418.	3.6	17
740	Effects of a High-Protein/Moderate-Carbohydrate Diet on Appetite, Gut Peptides, and Endocannabinoids—A Preview Study. Nutrients, 2019, 11, 2269.	4.1	17
741	Effects of carbohydrate restriction on postprandial glucose metabolism, β -cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E7-E18.	3.5	17
742	Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study. Nutrients, 2021, 13, 174.	4.1	17
743	GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E835-E845.	3.5	17
744	The Antiresorptive Effect of GIP, But Not GLP-2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study. Journal of Bone and Mineral Research, 2020, 36, 1448-1458.	2.8	17
745	On the Effects of Glucagon-Like Peptide-1 on Blood Glucose Regulation in Normal and Diabetic Subjects. Annals of the New York Academy of Sciences, 1996, 805, 729-736.	3.8	16
746	Meal-induced compositional changes in blood and saliva in persons with bulimia nervosa. American Journal of Clinical Nutrition, 2008, 87, 12-22.	4.7	16
747	Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. Biochemical and Biophysical Research Communications, 2012, 427, 91-95.	2.1	16
748	Incretin and Glucagon Levels in Adult Offspring Exposed to Maternal Diabetes in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1967-1975.	3.6	16
749	Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients. Nephrology Dialysis Transplantation, 2015, 30, 513-520.	0.7	16
750	Patient profiling for success after weight loss surgery (GO Bypass study): An interdisciplinary study protocol. Contemporary Clinical Trials Communications, 2018, 10, 121-130.	1.1	16
751	Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2613-2619.	3.6	16
752	Effects of active commuting and leisure-time exercise on appetite in individuals with overweight and obesity. Journal of Applied Physiology, 2019, 126, 941-951.	2.5	16
753	Effects of an intensive lifestyle intervention on the underlying mechanisms of improved glycaemic control in individuals with type 2 diabetes: a secondary analysis of a randomised clinical trial. Diabetologia, 2020, 63, 2410-2422.	6.3	16
754	GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats. American Journal of Physiology - Renal Physiology, 2020, 318, F1409-F1417.	2.7	16
755	Peptides in the regulation of glucagon secretion. Peptides, 2022, 148, 170683.	2.4	16
756	The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion. Metabolites, 2022, 12, 420.	2.9	16

#	Article	IF	CITATIONS
757	Pancreatic Spasmolytic Polypeptide, a Potential Growth Factor for the Intestine: Neural Control of Secretion. Digestion, 1990, 46, 226-231.	2.3	15
758	Isolation and Molecular Characterization of Porcine Calcitonin Gene-Related Peptide (CGRP) and Its Endocrine Effects in the Porcine Pancreas. Pancreas, 1998, 16, 195-204.	1.1	15
759	Functional and Immunohistochemical Evaluation of Porcine Neonatal Islet-Like Cell Clusters. Cell Transplantation, 2003, 12, 13-25.	2.5	15
760	Glucagon-like peptide 2 inhibits ghrelin secretion in humans. Regulatory Peptides, 2006, 137, 173-178.	1.9	15
761	Feeding an Elemental Diet <i>vs</i> a Milkâ€Based Formula Does Not Decrease Intestinal Mucosal Growth in Infant Pigs. Journal of Parenteral and Enteral Nutrition, 2006, 30, 32-39.	2.6	15
762	Copenhagen study of overweight patients with coronary artery disease undergoing low energy diet or interval training: the randomized CUT-IT trial protocol. BMC Cardiovascular Disorders, 2013, 13, 106.	1.7	15
763	Regulation of urea synthesis during the acute-phase response in rats. American Journal of Physiology - Renal Physiology, 2013, 304, G680-G686.	3.4	15
764	Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open, 2014, 4, e004227.	1.9	15
765	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1522-1528.	2.8	15
766	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. Peptides, 2015, 71, 229-231.	2.4	15
767	Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy, 2016, 16, 579-590.	3.1	15
768	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 312, R797-R805.	1.8	15
769	Augmented GLP-1 Secretion as Seen After Gastric Bypass May Be Obtained by Delaying Carbohydrate Digestion. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3233-3244.	3.6	15
770	High prevalence of prediabetes and metabolic abnormalities in overweight or obese schizophrenia patients treated with clozapine or olanzapine. CNS Spectrums, 2019, 24, 441-452.	1.2	15
771	Highâ€Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Betaâ€Adrenoceptor Blockade: A Randomized Clinical Trial. Journal of the American Heart Association, 2020, 9, e016828.	3.7	15
772	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. European Journal of Endocrinology, 2021, 184, 383-394.	3.7	15
773	Fiber mixture-specific effect on distal colonic fermentation and metabolic health in lean but not in prediabetic men. Gut Microbes, 2022, 14, 2009297.	9.8	15
774	Glicentin is present in the pig pancreas. FEBS Letters, 1985, 179, 1-6.	2.8	14

#	Article	IF	CITATIONS
775	Galanin: Distribution and Effect on Contractile Activity and Release of Vasoactive Intestinal Polypeptide from the Isolated Perfused Porcine Ileum. Digestion, 1990, 47, 191-199.	2.3	14
776	Tachykinins May Mediate Capsaicin-Induced, But Not Vagally Induced Motility in Porcine Antrum. Peptides, 1997, 18, 1511-1516.	2.4	14
777	Gastrointestinal function and metabolic control after construction of an orthotopic ileal neobladder in bladder cancer. Scandinavian Journal of Urology and Nephrology, 2007, 41, 14-19.	1.4	14
778	Angiotensin-converting enzyme activity and cognitive impairment during hypoglycaemia in healthy humans. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2008, 9, 37-48.	1.7	14
779	Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 297, R1554-R1562.	1.8	14
780	The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. American Journal of Physiology - Renal Physiology, 2012, 302, G815-G823.	3.4	14
781	Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrology Dialysis Transplantation, 2014, 29, 119-127.	0.7	14
782	The Use of Gastrostomy Tube for the Long-Term Remission of Hyperinsulinemic Hypoglycemia After Roux-en-y Gastric Bypass: A Case Report. AACE Clinical Case Reports, 2015, 1, e84-e87.	1.1	14
783	Hypoglycemia-Associated EEG Changes Following Antecedent Hypoglycemia in Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, 85-90.	4.4	14
784	Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 1101-1111.	2.2	14
785	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. Diabetologia, 2017, 60, 1344-1353.	6.3	14
786	Ghrelin secretion in humans – a role for the vagus nerve?. Neurogastroenterology and Motility, 2018, 30, e13295.	3.0	14
787	Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels. Journal of Nutrition and Metabolism, 2018, 2018, 1-11.	1.8	14
788	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. Journal of Clinical Medicine, 2020, 9, 3213.	2.4	14
789	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 11± Mutation Carriers. Diabetes, 2020, 69, 1989-2002.	0.6	14
790	Doseâ€dependent efficacy of the glucoseâ€dependent insulinotropic polypeptide (<scp>GIP)</scp> receptor antagonist <scp>GIP</scp> (3â€30) <scp>NH₂</scp> on <scp>GIP</scp> actions in humans. Diabetes, Obesity and Metabolism, 2021, 23, 68-74.	4.4	14
791	Gastrointestinal Hormones and β-Cell Function After Gastric Bypass and Sleeve Gastrectomy: A Randomized Controlled Trial (Oseberg). Journal of Clinical Endocrinology and Metabolism, 2022, 107, e756-e766.	3.6	14
792	Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R-dependent manner. JCI Insight, 2021, 6, .	5.0	14

#	Article	IF	CITATIONS
793	GIP-induced vasodilation in human adipose tissue involves capillary recruitment. Endocrine Connections, 2019, 8, 806-813.	1.9	14
794	Do glucagonomas always produce glucagon?. Bosnian Journal of Basic Medical Sciences, 2016, 16, 1-7.	1.0	14
795	Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture. Diabetes, 2021, 70, 2468-2475.	0.6	14
796	Extreme duration exercise affects old and younger men differently. Acta Physiologica, 2022, 235, e13816.	3.8	14
797	The Gastric Acid Secretagogue Gastrin-Releasing Peptide and the Inhibitor Oxyntomodulin Do Not Exert Their Effect Directly on the Parietal Cell in the Rat. Digestion, 1988, 40, 144-151.	2.3	13
798	Somatostatinand Prosomatostatin Immunoreactive Nerve Fibers in the Bovine Pineal Gland. Neuroendocrinology, 1992, 56, 278-283.	2.5	13
799	Mechanism-based population modelling for assessment of L-cell function based on total GLP-1 response following an oral glucose tolerance test. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 713-725.	1.8	13
800	A Pilot Study Examining the Relationship among Crohn Disease Activity, Glucagon-Like Peptide-2 Signalling and Intestinal Function in Pediatric Patients. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 587-592.	1.7	13
801	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E284-E291.	3.5	13
802	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. Diabetes Care, 2018, 41, 1260-1267.	8.6	13
803	Fatty Liver Among Adolescent Offspring of Women With Type 1 Diabetes (the EPICOM Study). Diabetes Care, 2019, 42, 1560-1568.	8.6	13
804	Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating Time (RESET) study. BMJ Open, 2020, 10, e037166.	1.9	13
805	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. International Journal of Obesity, 2020, 44, 1872-1883.	3.4	13
806	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E956-E964.	3.5	13
807	Acute Effects of Three Different Meal Patterns on Postprandial Metabolism in Older Individuals with a Risk Phenotype for Cardiometabolic Diseases: A Randomized Controlled Crossover Trial. Molecular Nutrition and Food Research, 2020, 64, e1901035.	3.3	13
808	Factors Associated with Favorable Changes in Food Preferences After Bariatric Surgery. Obesity Surgery, 2021, 31, 3514-3524.	2.1	13
809	Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men. Diabetes, Obesity and Metabolism, 2021, 23, 1834-1842.	4.4	13
810	Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats. PLoS ONE, 2017, 12, e0181453.	2.5	13

#	Article	IF	CITATIONS
811	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. Pharmacological Research, 2022, 176, 106058.	7.1	13
812	Nervous control of gastro-pancreatic somatostatin secretion in pigs. Peptides, 1981, 2, 215-221.	2.4	12
813	Pigs produce only a single form of CGRP, part of which is processed to fragments. Peptides, 1994, 15, 89-94.	2.4	12
814	Dose response of continuous subcutaneous infusion of recombinant glucagonâ€like peptideâ€1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2014, 16, 451-456.	4.4	12
815	Distal Gastrectomy in Pancreaticoduodenectomy is Associated with Accelerated Gastric Emptying, Enhanced Postprandial Release of GLP-1, and Improved Insulin Sensitivity. Journal of Gastrointestinal Surgery, 2014, 18, 52-59.	1.7	12
816	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetesa protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	1.9	12
817	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4377-4384.	3.6	12
818	Major rapid weight loss induces changes in cardiac repolarization. Journal of Electrocardiology, 2016, 49, 467-472.	0.9	12
819	Acute effects of glucagon-like peptide-1, GLP-1 _{9-36 amide} , and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers. Physiological Reports, 2017, 5, e13102.	1.7	12
820	DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity. PLoS ONE, 2017, 12, e0181880.	2.5	12
821	Reduced GLP-1 Secretion at 30 Minutes After a 75-g Oral Glucose Load Is Observed in Gestational Diabetes Mellitus: A Prospective Cohort Study. Diabetes, 2018, 67, 2650-2656.	0.6	12
822	Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects. Nutrients, 2018, 10, 1285.	4.1	12
823	Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses. BMC Genetics, 2018, 19, 15.	2.7	12
824	Effects of Exercise Training and IL-6 Receptor Blockade on Gastric Emptying and GLP-1 Secretion in Obese Humans: Secondary Analyses From a Double Blind Randomized Clinical Trial. Frontiers in Physiology, 2019, 10, 1249.	2.8	12
825	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e502-e510.	3.6	12
826	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. Journal of the Endocrine Society, 2020, 4, bvaa097.	0.2	12
827	Enteroendocrine K Cells Exert Complementary Effects to Control Bone Quality and Mass in Mice. Journal of Bone and Mineral Research, 2020, 35, 1363-1374.	2.8	12
828	The Renal Extraction and the Natriuretic Action of GLP-1 in Humans Depend on Interaction With the GLP-1 Receptor. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e11-e19.	3.6	12

#	Article	IF	CITATIONS
829	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. European Journal of Endocrinology, 2021, 185, 343-353.	3.7	12
830	Proglucagon Processing Profile in Canine L Cells Expressing Endogenous Prohormone Convertase 1/3 and Prohormone Convertase 2. Endocrinology, 1999, 140, 4800-4808.	2.8	12
831	The diurnal variation of bone formation is attenuated in adult patients with type 2 diabetes. European Journal of Endocrinology, 2019, 181, 221-231.	3.7	12
832	Corticotropin-Releasing Activity of Gastrin-Releasing Peptide in Normal Men*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 1291-1295.	3.6	11
833	Peptide-evoked release of amylase from isolated acini of the rat parotid gland. Regulatory Peptides, 1994, 51, 237-254.	1.9	11
834	6 Gut hormones and intestinal function. Bailliere's Clinical Endocrinology and Metabolism, 1994, 8, 137-164.	1.0	11
835	Use of Antagonists to Define Tachykininergic Control of Intestinal Motility in Pigs. Peptides, 1997, 18, 373-379.	2.4	11
836	Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. European Journal of Endocrinology, 2002, 146, 397-405.	3.7	11
837	Effects of oleic acid and olive oil on gastric emptying, gut hormone secretion andÂappetite in lean and overweight or obese males. E-SPEN Journal, 2013, 8, e8-e14.	0.5	11
838	Early growth and postprandial appetite regulatory hormone responses. British Journal of Nutrition, 2013, 110, 1591-1600.	2.3	11
839	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open, 2013, 3, e002764.	1.9	11
840	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. European Journal of Endocrinology, 2015, 173, 205-215.	3.7	11
841	Gastrointestinal motility in patients with endâ€stage renal disease on chronic hemodialysis. Neurogastroenterology and Motility, 2019, 31, e13554.	3.0	11
842	Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model. American Journal of Physiology - Renal Physiology, 2019, 316, G641-G652.	3.4	11
843	Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet. BMJ Open, 2019, 9, e031431.	1.9	11
844	Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction. International Journal of Cardiology, 2019, 283, 28-34.	1.7	11
845	Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide–Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes. Diabetes, 2020, 69, 146-157. 	0.6	11
846	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. Diabetes, 2020, 69, 2619-2629.	0.6	11

#	Article	IF	CITATIONS
847	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. Diabetologia, 2020, 63, 1285-1298.	6.3	11
848	Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent. Neurochemistry International, 2020, 138, 104772.	3.8	11
849	Glucagon-Like Peptide 1 and Atrial Natriuretic Peptide in a Female Mouse Model of Obstructive Pulmonary Disease. Journal of the Endocrine Society, 2020, 4, bvz034.	0.2	11
850	Pharmacological activation of TGR5 promotes intestinal growth via a GLP-2-dependent pathway in mice. American Journal of Physiology - Renal Physiology, 2020, 318, G980-G987.	3.4	11
851	Metformin Stimulates Intestinal Glycolysis and Lactate Release: A singleâ€Dose Study of Metformin in Patients With Intrahepatic Portosystemic Stent. Clinical Pharmacology and Therapeutics, 2021, 110, 1329-1336.	4.7	11
852	Long-acting glucagon-like peptide-1 receptor agonist—status December 2018. Annals of Translational Medicine, 2019, 7, 83-83.	1.7	11
853	Tachykinins stimulate release of peptide hormones (glucagon-like peptide-1) and paracrine (somatostatin) and neurotransmitter (vasoactive intestinal polypeptide) from porcine ileum through NK-1 receptors. Digestive Diseases and Sciences, 1999, 44, 1273-1281.	2.3	10
854	Milrinone efficiently potentiates insulin secretion induced by orally but not intravenously administered glucose in C57BL6J mice. European Journal of Pharmacology, 2004, 498, 319-323.	3.5	10
855	Cognitive performance, symptoms and counter-regulation during hypoglycaemia in patients with type 1 diabetes and high or low renin-angiotensin system activity. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 216-229.	1.7	10
856	Glucagon likeâ€peptide 1 receptor and the liver. Liver International, 2011, 31, 1243-1245.	3.9	10
857	Peptide YY3-36 and glucagon-like peptide-1 in functional dyspepsia. Secretion and role in symptom generation. Scandinavian Journal of Gastroenterology, 2016, 51, 400-409.	1.5	10
858	The Gut: A Key to the Pathogenesis of Type 2 Diabetes?. Metabolic Syndrome and Related Disorders, 2017, 15, 259-262.	1.3	10
859	Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. Diabetes Care, 2018, 41, 797-806.	8.6	10
860	The effect of casein, hydrolyzed casein, and whey proteins on urinary and postprandial plasma metabolites in overweight and moderately obese human subjects. Journal of the Science of Food and Agriculture, 2018, 98, 5598-5605.	3.5	10
861	Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. Nutrition and Diabetes, 2018, 8, 2.	3.2	10
862	Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease. Diabetology and Metabolic Syndrome, 2019, 11, 42.	2.7	10
863	Bariatric surgery—which procedure is the optimal choice?. Lancet, The, 2019, 393, 1263-1264.	13.7	10
864	Energy intake, gastrointestinal transit, and gut hormone release in response to oral triglycerides and fatty acids in men with and without severe obesity. American Journal of Physiology - Renal Physiology, 2019, 316, G332-G337.	3.4	10

#	Article	IF	CITATIONS
865	A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals. Obesity Surgery, 2020, 30, 1605-1610.	2.1	10
866	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. Diabetes Care, 2020, 43, 2889-2893.	8.6	10
867	A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia. Frontiers in Endocrinology, 2020, 11, 608248.	3.5	10
868	Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial. Scandinavian Journal of Clinical and Laboratory Investigation, 2020, 80, 401-407.	1.2	10
869	Nutrient Restriction has Limited Short-Term Effects on Gut, Immunity, and Brain Development in Preterm Pigs. Journal of Nutrition, 2020, 150, 1196-1207.	2.9	10
870	Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass. Obesity Surgery, 2020, 30, 1038-1045.	2.1	10
871	Intestinal Adaptation upon Chemotherapy-Induced Intestinal Injury in Mice Depends on GLP-2 Receptor Activation. Biomedicines, 2021, 9, 46.	3.2	10
872	Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V. Scientific Reports, 2021, 11, 12253.	3.3	10
873	Fortifying a meal with oyster mushroom powder beneficially affects postprandial glucagon-like peptide-1, non-esterified free fatty acids and hunger sensation in adults with impaired glucose tolerance: a double-blind randomized controlled crossover trial. European Journal of Nutrition, 2022, 61, 687-701.	3.9	10
874	GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150049.	0.5	10
875	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	10
876	GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. Current Opinion in Pharmacology, 2022, 63, 102189.	3.5	10
877	PACAP 1-27 and 1-38 in the Porcine Pancreas: Occurrence, Localization, and Effects. Annals of the New York Academy of Sciences, 1996, 805, 521-535.	3.8	9
878	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. BMJ Open, 2013, 3, e003834.	1.9	9
879	Infrared thermographic assessment of changes in skin temperature during hypoglycaemia in patients with type 1 diabetes. Diabetologia, 2015, 58, 1898-1906.	6.3	9
880	The glucagon like peptide-2 â€~axis': Capacity for production and response following intestinal resection or repair of gastroschisis in infants. Journal of Pediatric Surgery, 2018, 53, 898-904.	1.6	9
881	The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial. Lipids in Health and Disease, 2018, 17, 295.	3.0	9
882	Glucose Tolerance Tests and Osteocalcin Responses in Healthy People. Frontiers in Endocrinology, 2018, 9, 356.	3.5	9

#	Article	IF	CITATIONS
883	Glucagon-Like Peptide-1 Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1085-1091.	2.0	9
884	Pre-meal and postprandial lipaemia in subjects with the metabolic syndrome: effects of timing and protein quality (randomised crossover trial). British Journal of Nutrition, 2019, 121, 312-321.	2.3	9
885	Neuromedin U Does Not Act as a Decretin in Rats. Cell Metabolism, 2019, 29, 719-726.e5.	16.2	9
886	Glucose homeostasis in statin users—The LIFESTAT study. Diabetes/Metabolism Research and Reviews, 2019, 35, e3110.	4.0	9
887	A pre-meal of whey proteins induces differential effects on glucose and lipid metabolism in subjects with the metabolic syndrome: a randomised cross-over trial. European Journal of Nutrition, 2019, 58, 755-764.	3.9	9
888	No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled <scp>PREâ€D</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 530-539.	4.4	9
889	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. Clinical Nutrition, 2021, 40, 1013-1021.	5.0	9
890	Dietary Fiber Is Essential to Maintain Intestinal Size, L-Cell Secretion, and Intestinal Integrity in Mice. Frontiers in Endocrinology, 2021, 12, 640602.	3.5	9
891	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. Diabetes, 2021, 70, 1347-1356.	0.6	9
892	Counterregulatory responses to postprandial hypoglycemia after Roux-en-Y gastric bypass. Surgery for Obesity and Related Diseases, 2021, 17, 55-63.	1.2	9
893	Glucagon–how to prove its role in amino acid metabolism. European Journal of Clinical Investigation, 1983, 13, 107-108.	3.4	8
894	Cerebrovascular changes following administration of gammaglobulins against substance P or calcitonin gene related peptide in monkey with subarachnoid haemorrhage. British Journal of Neurosurgery, 1993, 7, 507-518.	0.8	8
895	Glucagon-Like Peptide 1: On Its Way to Clinical Application. Digestion, 1993, 54, 339-340.	2.3	8
896	Posttranslational Processing of Proglucagon and Postsecretory Fate of Proglucagon Products. Frontiers in Diabetes, 1997, 13, 24-48.	0.4	8
897	Vagal afferents are essential for maximal resection-induced intestinal adaptive growth in orally fed rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R1256-R1264.	1.8	8
898	Differential effects of secretinâ€fragments imply a dual mechanism of action for secretin. International Journal of Peptide and Protein Research, 1991, 37, 134-139.	0.1	8
899	Increased Postprandial Response of Glucagon-Like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency. Pancreatology, 2010, 10, 201-207.	1.1	8
900	A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failure. Journal of Pediatric Surgery, 2017, 52, 749-754.	1.6	8

#	Article	IF	CITATIONS
901	Mathematical Modelling of Glucoseâ€Dependent Insulinotropic Polypeptide and Glucagonâ€like Peptideâ€1 following Ingestion of Glucose. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 290-297.	2.5	8
902	Clucose ingestion causes cardiac repolarization disturbances in type 1 long QT syndrome patients and healthy subjects. Heart Rhythm, 2017, 14, 1165-1170.	0.7	8
903	Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice. Physiological Reports, 2018, 6, e13788.	1.7	8
904	Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovascular Diabetology, 2019, 18, 130.	6.8	8
905	Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 266-275.	3.6	8
906	The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study. Clinical Nutrition ESPEN, 2020, 39, 46-52.	1.2	8
907	Cerebral effects of glucagonâ€like peptideâ€1 receptor blockade before and after <scp>Rouxâ€enâ€Y</scp> gastric bypass surgery in obese women: A proofâ€ofâ€concept restingâ€state <scp>functional MRI</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 415-424.	4.4	8
908	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E671-E679.	3.5	8
909	Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. BMJ Open Gastroenterology, 2021, 8, e000604.	2.7	8
910	Effects of prebiotics on postprandial GLPâ€1, GLPâ€2 and glucose regulation in patients with type 2 diabetes: A randomised, doubleâ€blind, placeboâ€controlled crossover trial. Diabetic Medicine, 2021, 38, e14657.	2.3	8
911	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. Bone, 2021, 152, 116065.	2.9	8
912	Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls. World Journal of Gastroenterology, 2006, 12, 1874.	3.3	8
913	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. Clinical and Translational Gastroenterology, 2020, 11, e00257.	2.5	8
914	Expression Profile of the GLP-1 Receptor in the Gastrointestinal Tract and Pancreas in Adult Female Mice. Endocrinology, 2022, 163, .	2.8	8
915	Molecular and inÂvivo phenotyping of missense variants of the human glucagon receptor. Journal of Biological Chemistry, 2022, 298, 101413.	3.4	8
916	The Role of D-allulose and Erythritol on the Activity of the Gut Sweet Taste Receptor and Gastrointestinal Satiation Hormone Release in Humans: A Randomized, Controlled Trial. Journal of Nutrition, 2022, 152, 1228-1238.	2.9	8
917	Measurement of plasma glucagon in humans: A shift in the performance of a current commercially available radioimmunoassay kit. Diabetes, Obesity and Metabolism, 2022, 24, 1182-1184.	4.4	8
918	The effect of curcumin on hepatic fat content in individuals with obesity. Diabetes, Obesity and Metabolism, 2022, 24, 2192-2202.	4.4	8

#	Article	IF	CITATIONS
919	Nerve Fibers in the Rat Posterior Pituitary Lobe Contain Prosomatostatin (1–64). Neuroendocrinology, 1991, 54, 469-476.	2.5	7
920	Regulation of Motilin Release from Isolated Perfused Pig Duodenum. Digestion, 1996, 57, 341-348.	2.3	7
921	Inhibition of human gastric lipase by intraduodenal fat involves glucagon-like peptide-1 and cholecystokinin. Regulatory Peptides, 1999, 80, 101-106.	1.9	7
922	IL-6 has no acute effect on the regulation of urea synthesisin vivoin rats. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 150-156.	1.2	7
923	Addition of Rye Bran and Pea Fiber to Pork Meatballs Enhances Subjective Satiety in Healthy Men, but Does Not Change Glycemic or Hormonal Responses: A Randomized Crossover Meal Test Study. Journal of Nutrition, 2017, 147, jn250332.	2.9	7
924	Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2581-2592.	3.6	7
925	Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine. Journal of Visualized Experiments, 2019, , .	0.3	7
926	Intestinal sensing and handling of dietary lipids in gastric bypass–operated patients and matched controls. American Journal of Clinical Nutrition, 2020, 111, 28-41.	4.7	7
927	Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass. Journal of Bone and Mineral Metabolism, 2020, 38, 117-125.	2.7	7
928	In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients. Neurogastroenterology and Motility, 2020, 32, e13759.	3.0	7
929	Appetite Control across the Lifecourse: The Acute Impact of Breakfast Drink Quantity and Protein Content. The Full4Health Project. Nutrients, 2020, 12, 3710.	4.1	7
930	Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass. Frontiers in Endocrinology, 2021, 12, 681116.	3.5	7
931	Postprandial renal haemodynamic effects of the dipeptidyl peptidaseâ€4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (<scp>RENALIS</scp>): A predefined substudy of a randomized, doubleâ€blind trial. Diabetes, Obesity and Metabolism, 2022, 24, 115-124.	4.4	7
932	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. PLoS ONE, 2016, 11, e0154727.	2.5	7
933	Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocrine Connections, 2019, 8, 1372-1382.	1.9	7
934	Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150105.	0.5	7
935	Congenital Glucagon-like Peptide-1 Deficiency in the Pathogenesis of Protracted Diarrhea in Mitchell–Riley Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1084-e1090. ———————————————————————————————————	3.6	7
936	Glucagonâ€like peptideâ€1: Are its roles as endogenous hormone and therapeutic wizard congruent?. Journal of Internal Medicine, 2022, 291, 557-573.	6.0	7

#	Article	IF	CITATIONS
937	Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1569-1576.	3.6	7
938	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. Scandinavian Journal of Clinical and Laboratory Investigation, 2022, 82, 75-83.	1.2	7
939	Glucoseâ€dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat dietâ€fed mice. British Journal of Pharmacology, 2022, 179, 4486-4499.	5.4	7
940	Heterogeneity of immunoreactive gastric inhibitory polypeptide in the plasma of newly diagnosed type 1 (insulin-dependent) diabetics. European Journal of Endocrinology, 1987, 114, 74-83.	3.7	6
941	Somatostatin Inhibits Neurally Stimulated Pancreatic Secretion Indirectly. Pancreas, 1990, 5, 611-614.	1.1	6
942	Treatment of Type 2 diabetes mellitus based on glucagon-like peptide-1. Expert Opinion on Investigational Drugs, 1999, 8, 1409-1415.	4.1	6
943	The use of glycaemic index tables to predict glycaemic index of breakfast meals. British Journal of Nutrition, 2005, 94, 135-136.	2.3	6
944	Pharmacology of GLP-1-based therapies. British Journal of Diabetes and Vascular Disease, 2008, 8, S10-S18.	0.6	6
945	Impact of Exogenous Hyperglucagonemia on Postprandial Concentrations of Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4061-4065.	3.6	6
946	Pancreatic Î ² -cell responses to GLP-1 after near-normalization of blood glucose in patients with type 2 diabetes. Regulatory Peptides, 2010, 160, 175-180.	1.9	6
947	Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?. Diabetologia, 2013, 56, 1869-1872.	6.3	6
948	The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract. Scandinavian Journal of Gastroenterology, 2014, 49, 1143-1149.	1.5	6
949	Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1036-1045.	1.7	6
950	Pancreatic Polypeptide in Parkinson's Disease: A Potential Marker of Parasympathetic Denervation. Journal of Parkinson's Disease, 2017, 7, 645-652.	2.8	6
951	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. Scientific Reports, 2019, 9, 15154.	3.3	6
952	Bile Modulates Secretion of Incretins and Insulin: A Study of Human Extrahepatic Cholestasis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2685-2694.	3.6	6
953	Relationship between biochemical and symptomatic hypoglycemia after RYGB. Responses to a mixed meal test: a case-control study. Surgery for Obesity and Related Diseases, 2020, 16, 1179-1185.	1.2	6
954	Increased oral sodium chloride intake in humans amplifies selectively postprandial GLPâ€1 but not GIP, CCK, and gastrin in plasma. Physiological Reports, 2020, 8, e14519.	1.7	6

#	Article	IF	CITATIONS
955	Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report. BMC Endocrine Disorders, 2020, 20, 38.	2.2	6
956	What is Diabetes Remission?. Diabetes Therapy, 2021, 12, 641-646.	2.5	6
957	Effects of a Self-Prepared Carbohydrate-Reduced High-Protein Diet on Cardiovascular Disease Risk Markers in Patients with Type 2 Diabetes. Nutrients, 2021, 13, 1694.	4.1	6
958	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 77-87.	3.6	6
959	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. Endocrine Connections, 2020, 9, 747-754.	1.9	6
960	Glucagon Clearance Is Preserved in Type 2 Diabetes. Diabetes, 2022, 71, 73-82.	0.6	6
961	Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. IDrugs: the Investigational Drugs Journal, 2008, 11, 497-501.	0.7	6
962	Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Diabetes Care, 2022, 45, 1476-1481.	8.6	6
963	Arginine-induced glucagon secretion and glucagon-induced enhancement of amino acid catabolism are not influenced by ambient glucose levels in mice. American Journal of Physiology - Endocrinology and Metabolism, 2022, 323, E207-E214.	3.5	6
964	Stripping of endogenous ligands from antisera against glucagon. Journal of Immunological Methods, 1983, 58, 83-91.	1.4	5
965	Secretion uncouples glucose inhibition of glucagon-producing cells resulting in a simultaneous stimulation of both glucagon and insulin release. Regulatory Peptides, 1988, 23, 315-322.	1.9	5
966	Enteroglucagon. Advances in Metabolic Disorders, 1988, , 393-419.	0.3	5
967	Important species differences regarding lymph contribution to gut hormone responses. Peptides, 2015, 71, 28-31.	2.4	5
968	Regulation of Pancreatic α-Cell Function and Proliferation by Bone Morphogenetic Protein 4 (BMP4) In Vitro. Endocrinology, 2016, 157, 3809-3820.	2.8	5
969	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. EBioMedicine, 2018, 28, 234-240.	6.1	5
970	Abscisic acid stimulates the release of insulin and of GLPâ€l in the rat perfused pancreas and intestine. Diabetes/Metabolism Research and Reviews, 2019, 35, e3102.	4.0	5
971	Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2019, 14, 243-257.	2.4	5
972	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 242.	3.5	5

#	Article	IF	CITATIONS
973	The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults. IJC Heart and Vasculature, 2019, 22, 139-144.	1.1	5
974	Gastric Bypass with Different Biliopancreatic Limb Lengths Results in Similar Post-absorptive Metabolomics Profiles. Obesity Surgery, 2020, 30, 1068-1078.	2.1	5
975	CCKâ€l and CCKâ€2 receptor agonism do not stimulate GLPâ€l and neurotensin secretion in the isolated perfused rat small intestine or GLPâ€l and PYY secretion in the rat colon. Physiological Reports, 2020, 8, e14352.	1.7	5
976	Body weight and metabolic risk factors in patients with type 2 diabetes on a self-selected high-protein low-carbohydrate diet. European Journal of Nutrition, 2021, 60, 4473-4482.	3.9	5
977	The liver-alpha-cell axis after a mixed meal and during weight loss in type 2 diabetes. Endocrine Connections, 2021, 10, 1101-1110.	1.9	5
978	Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E443-E452.	3.5	5
979	Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men. Endocrine Connections, 2019, 8, 1607-1617.	1.9	5
980	Role of fasting duration and weekday in incretin and glucose regulation. Endocrine Connections, 2020, 9, 279-288.	1.9	5
981	Effects of shortâ€acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 221-227.	4.4	5
982	Novel agonist―and antagonistâ€based radioligands for the GLPâ€2 receptor ―useful tools for studies of basic GLPâ€2R pharmacology. British Journal of Pharmacology, 2021, , .	5.4	5
983	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption. , 2022, 1, 299-312.		5
984	Glucose- and Bile Acid-Stimulated Secretion of Gut Hormones in the Isolated Perfused Intestine Is Not Impaired in Diet-Induced Obese Mice. Frontiers in Endocrinology, 2022, 13, .	3.5	5
985	Acute concomitant glucoseâ€dependent insulinotropic polypeptide receptor antagonism during glucagonâ€like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 2022, 24, 1882-1887	4.4	5
986	Nâ€terminal alterations turn the gut hormone GLPâ€2 into an antagonist with gradual loss of GLPâ€2 receptor selectivity towards more GLPâ€1 receptor interaction. British Journal of Pharmacology, 2022, 179, 4473-4485.	5.4	5
987	Discovery of the GI Effects of GLP-1: An Historical Perspective. Digestive Diseases and Sciences, 2022, 67, 2716-2720.	2.3	5
988	Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial. Clinical Nutrition, 2022, , .	5.0	5
989	Nervous control of pancreatic endocrine secretion in pigs IV. The effect of somatostatin on the insulin and glucagon responses to electrical vagal stimulation and to intraarterial acetylcholine. Acta Physiologica Scandinavica, 1981, 113, 273-278.	2.2	4
990	Role of gastrin-releasing peptide in pepsinogen secretion from the isolated perfused rat stomach. Regulatory Peptides, 1988, 23, 95-104.	1.9	4

#	Article	IF	CITATIONS
991	Neuropeptide Y (NPY) and vasoactive intestinal polypeptide (VIP), but not galanin, are autonomic cotransmitters in the porcine pancreas. International Journal of Gastrointestinal Cancer, 1991, 10, 133-41.	0.4	4
992	Treatment of type 2 diabetes with glucagonlike peptide 1. Current Opinion in Endocrinology, Diabetes and Obesity, 1998, 5, 108-115.	0.6	4
993	The antagonistic metabolite of GLP-1, GLP-1 (9-36)amide, does not influence gastric emptying and hunger sensations in man. Scandinavian Journal of Gastroenterology, 2007, 42, 28-33.	1.5	4
994	Plasma glucagon-like peptide 1 and peptide YY levels are not altered in symptomatic fructose-sorbitol malabsorption. Scandinavian Journal of Gastroenterology, 2008, 43, 1212-1218.	1.5	4
995	The Relationship between Glucagon-Like Peptide 2 and Feeding Intolerance in Preterm Infants. Journal of Tropical Pediatrics, 2009, 55, 276-277.	1.5	4
996	Effects of a meal rich in medium-chain saturated fat on postprandial lipemia in relatives of type 2 diabetics. Nutrition, 2013, 29, 1000-1006.	2.4	4
997	The insulinotropic effect of exogenous glucagonâ€ike peptideâ€1 is not affected by acute vagotomy in anaesthetized pigs. Experimental Physiology, 2016, 101, 895-912.	2.0	4
998	Glycaemic control and weight loss with semaglutide in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2017, 5, 315-317.	11.4	4
999	Relationship between Optimum Miniâ€doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes – A Simulation Study. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 322-330.	2.5	4
1000	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. BMC Endocrine Disorders, 2018, 18, 60.	2.2	4
1001	Renoprotective effects of dulaglutide in patients with T2DM and CKD. Nature Reviews Nephrology, 2018, 14, 659-660.	9.6	4
1002	Different Malabsorptive Obesity Surgery Interventions Result in Distinct Postprandial Amino Acid Metabolomic Signatures. Obesity Surgery, 2020, 30, 4019-4028.	2.1	4
1003	No effects of a 6â€week intervention with a glucagonâ€like peptideâ€1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1837-1846.	4.4	4
1004	Glucagon receptor signaling is not required for <i>N</i> -carbamoyl glutamate- and <scp>l</scp> -citrulline-induced ureagenesis in mice. American Journal of Physiology - Renal Physiology, 2020, 318, G912-G927.	3.4	4
1005	Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans. Endocrine Connections, 2021, 10, 205-213.	1.9	4
1006	Effect of 6 weeks of very lowâ€volume highâ€intensity interval training on oral glucoseâ€stimulated incretin hormone response. European Journal of Sport Science, 2022, 22, 381-389.	2.7	4
1007	β-Lactoglobulin Is Insulinotropic Compared with Casein and Whey Protein Ingestion during Catabolic Conditions in Men in a Double-Blinded Randomized Crossover Trial. Journal of Nutrition, 2021, 151, 1462-1472.	2.9	4
1008	What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?. Cell Reports Medicine, 2021, 2, 100284.	6.5	4

#	Article	IF	CITATIONS
1009	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia, 2021, 64, 2425-2431.	6.3	4
1010	Entero-Pancreatic Hormone Secretion, Gastric Emptying, and Glucose Absorption After Frequently Sampled Meal Tests. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e188-e204.	3.6	4
1011	Effects of a Lifestyle Intervention on Bone Turnover in Persons with Type 2 Diabetes: A Post Hoc Analysis of the U-TURN Trial. Medicine and Science in Sports and Exercise, 2022, 54, 38-46.	0.4	4
1012	Glucoseâ€dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, doubleâ€blind, placeboâ€controlled, crossover clinical trial. Diabetes, Obesity and Metabolism, 2022, 24, 142-147.	4.4	4
1013	Incretin hormones - an update. Scandinavian Journal of Clinical and Laboratory Investigation, 2001, 61, 75-85.	1.2	4
1014	THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin – physiology and pharmacology. European Journal of Endocrinology, 2022, 186, R93-R111.	3.7	4
1015	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Frontiers in Nutrition, 2022, 9, 889710.	3.7	4
1016	The Role of Gastrin-Releasing Peptide in Pancreatic Exocrine Secretion. Annals of the New York Academy of Sciences, 1988, 547, 234-241.	3.8	3
1017	Somatostatin release induced by gastrin-releasing peptide in man. Effect of proximal gastric vagotomy and cholinergic blockade. Regulatory Peptides, 1990, 29, 133-141.	1.9	3
1018	Young, low-birth-weight men are not more susceptible to the diabetogenic effects of a prolonged free fatty acid exposure than matched controls. Metabolism: Clinical and Experimental, 2005, 54, 1398-1406.	3.4	3
1019	New Horizons in Diabetes Therapy. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7, 49-55.	0.5	3
1020	Gut hormones and gastric bypass. Cardiovascular Endocrinology, 2016, 5, 69-74.	0.8	3
1021	Is glucagonâ€ike peptideâ€1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism, 2018, 20, 1937-1943.	4.4	3
1022	Treatment with GLP-1 Receptor Agonists. Endocrinology, 2018, , 1-45.	0.1	3
1023	GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals. Cardiovascular Diabetology, 2019, 18, 91.	6.8	3
1024	Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?. Lancet, The, 2019, 394, 4-6.	13.7	3
1025	Gastrointestinal motility, gut hormone secretion, and energy intake after oral loads of free fatty acid or triglyceride in older and middle-aged men. Appetite, 2019, 132, 18-24.	3.7	3
1026	Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e564-e574.	3.6	3

#	Article	IF	CITATIONS
1027	No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects. Peptides, 2020, 125, 170176.	2.4	3
1028	Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine- or Olanzapine-Treated, Prediabetic, Schizophrenia Patients. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
1029	Can Metabolite and Hormone Profiles Provide a Rationale for Choosing Between Bariatric Procedures?. Obesity Surgery, 2021, 31, 2174-2179.	2.1	3
1030	Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test. BMC Medical Genomics, 2021, 14, 3.	1.5	3
1031	Resistant Starch Combined with Whey Protein Increases Postprandial Metabolism and Lowers Glucose and Insulin Responses in Healthy Adult Men. Foods, 2021, 10, 537.	4.3	3
1032	Voices: Insulin and beyond. Cell Metabolism, 2021, 33, 692-699.	16.2	3
1033	Do sodiumâ€glucose coâ€transporterâ€2 inhibitors increase plasma glucagon by direct actions on the alpha cell? And does the increase matter for the associated increase in endogenous glucose production?. Diabetes, Obesity and Metabolism, 2021, 23, 2009-2019.	4.4	3
1034	Autonomic Diabetic Neuropathy Impairs Glucose and Dipeptidyl Peptidase 4 Inhibitor-Regulated Glucagon Concentration in Type 1 Diabetic Patients. Journal of Endocrinology and Metabolism, 2015, 5, 229-237.	0.4	3
1035	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. Diabetes, 2018, 67, 145-OR.	0.6	3
1036	1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon. Diabetes, 2019, 68, .	0.6	3
1037	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	3
1038	The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes. European Journal of Endocrinology, 2022, 186, 207-221.	3.7	3
1039	Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2021, 12, 793588.	4.8	3
1040	Glucagonâ€like peptideâ€1 effect on βâ€cell function varies according to diabetes remission status after Rouxâ€enâ€Y gastric bypass. Diabetes, Obesity and Metabolism, 2022, 24, 2081-2089.	4.4	3
1041	Oxidation/reduction explains heterogeneity of pancreatic somatostatin. FEBS Letters, 1991, 279, 237-239.	2.8	2
1042	Depletion of mucosal substance P in acute otitis media. Acta Oto-Laryngologica, 2004, 124, 794-797.	0.9	2
1043	Glucagon-Like Peptide-2 in Umbilical Cord Blood from Mature Infants. Neonatology, 2007, 91, 49-53.	2.0	2

1044 GLP 1/2, Enteroglucagon, Glicentin, and Oxyntomodulin. , 2013, , 1241-1250.

#	Article	IF	CITATIONS
1045	A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease. Case Reports in Gastroenterology, 2014, 8, 398-403.	0.6	2
1046	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. Endocrine Connections, 2014, 3, 193-199.	1.9	2
1047	Gastric bypass surgery has a weight-loss independent effect on post-challenge serum glucose levels. Diabetology and Metabolic Syndrome, 2015, 7, 69.	2.7	2
1048	Serum lipase activity and concentration during intravenous infusions of GLP-1 and PYY3-36 and after adÂlibitum meal ingestion in overweight men. Physiological Reports, 2016, 4, e12980.	1.7	2
1049	Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia. Endocrine Connections, 2016, 5, 53-60.	1.9	2
1050	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. Nutrients, 2020, 12, 2928.	4.1	2
1051	Lixisenatide in type 1 diabetes: A randomised control trial of the effect of lixisenatide on postâ€meal glucose excursions and glucagon in type 1 diabetes patients. Endocrinology, Diabetes and Metabolism, 2020, 3, e00130.	2.4	2
1052	Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays. Peptides, 2021, 136, 170457.	2.4	2
1053	Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women. Bone, 2021, 143, 115612.	2.9	2
1054	In patients with controlled acromegaly, indices of glucose homeostasis correlate with IGFâ€1 levels rather than with type of treatment. Clinical Endocrinology, 2021, 95, 65-73.	2.4	2
1055	Exploring the CLP-1–CLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography. BMJ Open Diabetes Research and Care, 2021, 9, e002083.	2.8	2
1056	Intestinal Growth in Glucagon Receptor Knockout Mice Is Not Associated With the Formation of AOM/DSS-Induced Tumors. Frontiers in Endocrinology, 2021, 12, 695145.	3.5	2
1057	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. European Journal of Endocrinology, 2021, 185, 23-32.	3.7	2
1058	Neurotensin secretion after Rouxâ€en‥ gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. Neurogastroenterology and Motility, 2021, , e14210.	3.0	2
1059	L-Cell Expression of Melanocortin-4-Receptor Is Marginal in Most of the Small Intestine in Mice and Humans and Direct Stimulation of Small Intestinal Melanocortin-4-Receptors in Mice and Rats Does Not Affect GLP-1 Secretion. Frontiers in Endocrinology, 2021, 12, 690387.	3.5	2
1060	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition. Diabetes, 2018, 67, 1942-P.	0.6	2
1061	After Roux-en-Y Gastric Bypass, Enterohepatic Bile Circulation Is Altered and Bile Acid Retention Increased while Bile Acid Homeostasis Remains Normal after Sleeve Gastrectomy. Diabetes, 2018, 67, .	0.6	2
1062	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. Endocrine Connections, 2020, 9, 1221-1232.	1.9	2

#	Article	IF	CITATIONS
1063	Opposing roles of the entero-pancreatic hormone urocortin-3 in glucose metabolism in rats. Diabetologia, 2022, 65, 1018-1031.	6.3	2
1064	Incretin based therapies: Do they hold their promise?. Journal of Diabetes, 2012, 4, 4-7.	1.8	1
1065	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. BMC Research Notes, 2014, 7, 326.	1.4	1
1066	Response to Comment on Færch et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 2015;64:2513–2525. Diabetes, 2015, 64, e30-e31.	0.6	1
1067	Surgical or medical therapy for patients with obesity and T2DM?. Nature Reviews Endocrinology, 2016, 12, 500-502.	9.6	1
1068	Treatment with GLP-1 Receptor Agonists. Endocrinology, 2018, , 571-615.	0.1	1
1069	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. Physiological Reports, 2018, 6, e13686.	1.7	1
1070	Glucose homeostasis and the gastrointestinal tract. , 2019, , 3-19.		1
1071	Assessment of Islet Alpha- and Beta-Cell Function. , 2019, , 37-74.		1
1072	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. Diabetes, Obesity and Metabolism, 2020, 22, 2161-2169.	4.4	1
1073	Effects of a whey protein preâ€meal on bone turnover in participants with and without type 2 diabetes—A post hoc analysis of a randomised, controlled, crossover trial. Diabetic Medicine, 2021, 38, e14471.	2.3	1
1074	Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery. American Journal of Physiology - Renal Physiology, 2021, 320, G753-G758.	3.4	1
1075	Pancreatic polypeptide: A potential biomarker of glucoseâ€dependent insulinotropic polypeptide receptor activation in vivo. Diabetic Medicine, 2021, 38, e14592.	2.3	1
1076	The Effect of Melatonin on Incretin Hormones: Results From Experimental and Randomized Clinical Studies. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5109-e5123.	3.6	1
1077	Impact of Polymorphism in the β2-Receptor Gene on Metabolic Responses to Repeated Hypoglycemia in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3194-e3205.	3.6	1
1078	The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection. Frontiers in Endocrinology, 0, 13, .	3.5	1
1079	Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in Beta Cell Function in Patients with Type 2 Diabetes. Diabetes, 0, , .	0.6	1
1080	Adrenocortical function after major gastric surgery. American Journal of Surgery, 1973, 126, 595-597.	1.8	0

#	Article	IF	CITATIONS
1081	Discussing the Role of Glucagonlike Peptide-I. Diabetes Care, 1992, 15, 1440-1441.	8.6	0
1082	Effects of GLP-1 on Gastric Acid and Pancreatic Exocrine Secretion and on Gastrointestinal Motility. Frontiers in Diabetes, 1997, 13, 194-206.	0.4	0
1083	The Authors Reply:. Kidney International, 2014, 85, 212-213.	5.2	0
1084	WEIGHT LOSS BUT NOT EXERCISE LOWERS GLUCAGON RESPONSE AND IMPROVES GLUCAGON-LIKE PEPTIDE-1 TO INSULIN RATIO IN PREDIABETIC PATIENTS WITH CORONARY ARTERY DISEASE: THE RANDOMIZED CUT-IT TRIAL. Journal of the American College of Cardiology, 2015, 65, A1511.	2.8	0
1085	Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics, 2016, 12, 1.	3.0	0
1086	Response to Letter to the Editor: "Hemodynamic Effects of Glucagon: A Literature Review― Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4480-4481.	3.6	0
1087	Gastric Emptying and Distal Gastrectomy Independently Enhance Postprandial Glucagon-Like Peptide-1 Release After a Mixed Meal and Improve Glycemic Control in Subjects Having Undergone Pancreaticoduodenectomy. Pancreas, 2019, 48, 953-957.	1.1	0
1088	The effect of preceding glucose decline rate on lowâ€dose glucagon efficacy in individuals with type 1 diabetes: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2021, 23, 1057-1062.	4.4	0
1089	Role of fasting duration and weekday in incretin and glucose regulation. Endocrine Connections, 2021, 10, X2-X3.	1.9	0
1090	Salivary ghrelin response to drinks varying in protein content and quantity and association with energy intake and appetite Physiology and Behavior, 2021, 242, 113622.	2.1	0
1091	Enteroglucagon. , 2004, , 709-715.		0
1092	Glucagonlike Peptides 1 and 2, Enteroglucagon, Glicentin, and Oxyntomodulin. , 2006, , 1057-1064.		0
1093	Synergistic effect of supplemental enteral nutrients (SEN) and glucagonâ€ike peptideâ€2 (GLPâ€2) in intestinal adaptation in a rat model of human short bowel syndrome (SBS). FASEB Journal, 2006, 20, .	0.5	Ο
1094	Glucagon-like Peptides and Insulin Sensitivity. , 2008, , 233-254.		0
1095	The contribution of gastrointestinal appetite hormones to proteinâ€induced satiety. FASEB Journal, 2012, 26, 40.5.	0.5	Ο
1096	Incretin hormones as a target for therapy. , 2016, , 11-30.		0
1097	Glucagon Processing. , 2019, , .		0
1098	Hepatic Bile Acid Reuptake in the Rat Depends on Bile Acid Conjugation but Not on Agonistic Properties towards FXR and TGR5. Molecules, 2020, 25, 2371.	3.8	0

#	Article	IF	CITATIONS
1099	Coming of Age for the Incretins. , 2008, , 269-290.		Ο
1100	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake. Obesity Surgery, 2022, 32, 1385-1390.	2.1	0
1101	Acute effects of linagliptin on intact and total glucagonâ€like peptideâ€1 and gastric inhibitory polypeptide levels in insulinâ€dependent type 2 diabetes patients with and without moderate renal impairment. Diabetes, Obesity and Metabolism, 2022, 24, 806-815.	4.4	0
1102	Long-term outcomes of dietary carbohydrate restriction for HbA1c reduction in type 2 diabetes mellitus are needed. Reply to Kang J and Ma E [letter]. Diabetologia, 2022, , 1.	6.3	0
1103	Early effects of Roux-en-Y gastric bypass on dietary fatty acid absorption and metabolism in people with obesity and normal glucose tolerance. International Journal of Obesity, 2022, 46, 1359-1365.	3.4	0
1104	Studies in Rats of Combined Muscle and Liver Perfusion and of Muscle Extract Indicate That Contractions Release a Muscle Hormone Directly Enhancing Hepatic Glycogenolysis. Journal of Personalized Medicine, 2022, 12, 837.	2.5	0